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EXAMINATION OF RACIAL/ETHNIC DISPARITIES IN OVARIAN CANCER STAGE OF 
DIAGNOSIS, SURGERY TREATMENT AND SURVIVAL: MULTILEVEL ANALYSIS OF 
2001—2012 SEER DATA 
 
by 
 
CHEN CHEN 
 
(Under the Direction of Yelena N. Tarasenko) 
 
ABSTRACT 
 
Context. Racial/ethnic disparities in cancer outcomes are major public health concerns. 
Ovarian cancer is the tenth most common cancer and the fifth leading cause of cancer-related 
deaths among women. Identifying individual- and contextual-level factors contributing to 
racial/ethnic disparities in ovarian cancer stage of diagnosis, surgery treatment, and survival is 
necessary for reducing and eliminating these disparities. 
Objective. The study aims to examine racial/ethnic disparities in ovarian cancer diagnosis, 
surgery treatment and survival outcomes; to explore individual- and contextual-level factors 
contributing to these disparities, and to examine the trend of ovarian cancer racial/ethnic disparities 
from 2001 to 2012. 
 Methods. The study was based on the Surveillance, Epidemiology, and End Results data. 
Multilevel binary logistic regressions were used for the analysis of racial/ethnic disparities in late 
stage diagnosis and receipt of surgery adjusted for both individual- and county-level factors, 
respectively. Multilevel Cox-proportional hazards models were applied to analyze the racial/ethnic 
disparities in ovarian cancer-cause specific mortality. Joinpoint regression models were used to 
analyze the trend of ovarian cancer racial/ethnic disparities over time.  
 Result. Adjusting for age at diagnosis, marital status, tumor pathological characteristics, 
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metro/nonmetro residence, and indicators of socioeconomic status of county residents, compared 
to Non-Hispanic white (NHW) patients, non-Hispanic black (NHB) patients have significantly 
higher probability of advanced stage diagnosis (75.44% vs. 69.52%; p=0.001), but this difference 
is only significant for patients living in counties with the employment rate ranked in the highest 
quartile. NHW patients have the highest adjusted probability of receiving surgery treatment 
(83.40%, 95%CI: 83.04% - 83.76%), whereas Hispanic patients (81.96%, 95%CI: 81.16% - 
82.76%) and NHB patients (77.65%, 95%CI: 76.73% - 78.58%) have the lowest adjusted 
probability (p <0.05). Compared to NHW patients, NHB patients have 24% increased hazards of 
ovarian cancer death (95% CI: 1.18 – 1.30, p<0.001). Both individual- and contextual-level factors 
contribute to racial/ethnic disparities in ovarian cancer. From 2001-2012, the extent of racial/ethnic 
disparities in ovarian cancer remained stable (p’s<0.05).  
 Conclusion. The associations between individual- and contextual-level factors and 
ovarian cancer outcomes vary by race/ethnicity and should be examined separately. Multilevel 
culturally tailored efforts are required to decrease racial/ethnic disparities in ovarian cancer.  
INDEX WORDS: Ovarian cancer, Diagnosis, Surgery, Survival, Racial/ethnic disparities, multi-
level, SEER 
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CHAPTER 1 
BACKGROUND 
Being the deadliest of gynecologic cancers, ovarian cancer is the eleventh most common 
cancer and the fifth leading cause of cancer-related deaths among women (Ovarian Cancer 
National Alliance, 2014a). According to the Surveillance, Epidemiology, and End Results (SEER) 
statistics, based on 2008-2012 cancer cases and deaths, the number of new cases of ovarian cancer 
was 12.1 per 100,000 women per year, and the number of deaths was 7.7 per 100,000 women per 
year (National Cancer Institute, 2015a). In 2011, there were approximately 188,867 women alive 
who had a history of ovarian cancer (National Cancer Institute, 2015a). It is estimated that, in 2015, 
21,290 women (i.e. 1.3% of all new cancer cases) will be diagnosed with and 14,180 women (i.e.  
2.4% of all cancer deaths) will die of ovarian cancer (National Cancer Institute, 2015a).  
Ovarian cancer is often diagnosed at a later stage due to vaguely presented symptoms and 
lack of reliable screening tests for general female population. Certain tests are available for 
assisting with diagnosis of women with high risk; however, the only way for definitive diagnose 
is through surgery and biopsy. Upon diagnosis, the treatment plan usually depends on the cancer 
stage and histology type. Surgery, chemotherapy and radiotherapy are the main treatments for 
ovarian cancer.  
Several genetic risk factors are associated with the development of ovarian cancer. For 
example, women with a family history of ovarian cancer are at increased risk (US Preventive 
Services Task Force [USPSTF], 2014a). Mutations in BRCA1 and BRCA2 genes are responsible 
for most inherited ovarian cancers, and the mutations in those two genes are also linked with high 
risk of inherited breast cancer (American Cancer Society, 2014c; Holschneider & Berek, 2000).   
Behavioral factors also contribute to the development of ovarian cancer. For example, 
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being obese and use of postmenopausal estrogen are associated with increased ovarian cancer risk 
(American Cancer Society, 2014c; National Cancer Institute, 2014). Because the development of 
ovarian cancer is associated with the number of lifetime ovulations, factors that reduce ovulation, 
such as pregnancy, breast feeding, and use of oral contraceptive pills, and previous hysterectomy 
or sterilization are associated with reduced ovarian cancer risk (Edmondson & Todd, 2008; 
Holschneider & Berek, 2000; National Cancer Institute, 2014). 
In addition to the genetic and behavioral risk factors, socioeconomic environment is an 
important factor which may influence ovarian cancer diagnosis, treatment and prognosis through 
differences in healthcare accessibility. Research has demonstrated a strong relationship between 
socioeconomic environment and healthcare accessibility (Breen & Figueroa, 1996; Coughlin, 
Leadbetter, Richards, & Sabatino, 2008; Kirby & Kaneda, 2005, 2006; Litaker, Koroukian, & Love, 
2005; Prentice, 2006). Management of ovarian cancer and related complications requires a long-
term and systematic approach. Living in a community with majority of residents characterized by 
low socio-economic status (SES) or rural communities where the allocation of medical resources 
is limited, may constrict people’s individual accessibility for healthcare services (Hendryx, Ahern, 
Lovrich & McCurdy, 2002; Kirby & Kaneda, 2005). 
SES has long been linked with race/ethnicity. There is also a significant interaction effect of 
race and SES on health outcomes. For example, based on the US National Health and Nutrition 
Examination Survey, Farmer and Ferraro found that the racial disparity between white and black 
adults in self-rated health was largest at the higher levels of SES. The finding may indicate that 
improvements in SES does not necessarily translate into improvements in health outcomes of 
people from different racial groups (Farmer & Ferraro, 2005). Despite improvements in cancer 
care during the past two decades, racial/ethnic disparities in ovarian cancer still exist in the United 
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States. According to the Centers for Disease Control and Prevention (CDC) 2011 statistics, white 
women had the highest incidence rate of ovarian cancer, followed by Hispanic, Asian/Pacific 
Islander, Black, and American Indian/Alaska Native women. White women also had the highest 
death rate of ovarian cancer, followed by Black, Hispanic, Asian/Pacific Islander, and American 
Indian/Alaska Native women (Centers for Disease Control and Prevention [CDC], 2014).  Racial 
disparities in ovarian cancer have been documented with respect to stage of diagnosis, treatment, 
and survival outcomes (Farley, Risinger, Rose, & Maxwell, 2007; Tammemagi, 2007; Terplan, 
Schluterman, McNamara, Tracy, & Temkin, 2012). However, the extent to which these disparities 
reflect unequal access to health care and whether the disparities can be explained by individual-
level, contextual-level characteristics or a combination thereof remains unclear.  
Further research is needed to identify contextual-level factors associated with racial/ethnic 
disparities in ovarian cancer outcomes. Lack of such knowledge is an important barrier to 
decreasing the health disparities in the United States. For other cancer diseases, contextual level 
SES has been found to be associated with disparities in cancer outcomes (Ward et al., 2004; Breen 
& Figueroa, 1996; Coughlin, et al., 2008; Robert et al., 2004). However the contribution of 
socioeconomic characteristics of community in ovarian cancer outcomes is not understood.  
Variations in US ovarian cancer outcomes by rurality is also unknown, especially based on 
national level data.  With the rapid urbanization, urban environments are more likely to see large 
disparities in socioeconomic status (Unite For Sight, 2014). Also, with the growth of minority 
population in rural areas, part of the health disparities may also be attributed to lifestyle differences 
(Unite For Sight, 2014).  As a result, although generally speaking, people living in rural areas are 
more likely to be of lower SES than their urban counterparts, the health disparity by rural/urban 
residence may not be fully explained by SES differences. Rural counties can have communities 
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with high SES, and rural/urban difference in health outcomes may also be attributed to factors such 
as differences in life styles and living environment. Examining rural/urban differences in health 
outcomes can provide insights on the development of policies to targeting rural areas.  
The effects of socioeconomic environment, rural/urban residence, and individual-level 
factors on development and prognosis of ovarian cancer disease are unknown. Study based on 
examination of individual-level factors have limited health policy and intervention development 
implications. Failure to consider potential interaction effects between multilevel factors may lead 
to unwise recommendation for policy development (e.g. inefficient allocation of medical resources) 
which may slow down the progress of health promotion. This study relies on constructs of a social 
ecological model which integrates multilevel factors and provides conceptual framework for 
studying the interaction effects of those factors on ovarian cancer health outcomes (Glanz, Rimer, 
& Viswanath, 2008). The main hypotheses of the study are (i) there are racial/ethnic disparities in 
ovarian cancer stage of diagnosis, receipt of surgery treatment and survival outcome, and (ii) both 
individual-level characteristics (such as age, marital status, and pathological characteristics) and 
contextual-level factors (such as county-level SES and metro/nonmetro residence) contribute to 
these racial/ethnic disparities.  
The study aims to examine racial/ethnic disparities in ovarian cancer diagnosis, surgery 
treatment and survival outcomes; explore individual- and contextual-level factors contributing to 
these disparities and examine trend in ovarian cancer racial/ethnic disparities from 2001 to 2012. 
The study findings are expected to provide insights into mechanisms through which ovarian cancer 
racial/ethnic disparities are developed; inform policy-makers about the subpopulation which 
suffers an excessive ovarian cancer burden, and update knowledge on the trend of ovarian cancer 
racial/ethnic disparities based on a national level cancer registry data.  
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CHAPTER 2 
LITERATURE REVIEW 
Ovarian Cancer: Symptoms, Diagnosis and Treatment 
The development of ovarian cancer can be accompanied by several symptoms. Some of the 
potential symptoms include pelvic mass, such as urinary frequency, pain, and constipation. There 
are also symptoms related to other intra-abdominal disease, including disease of or invading the 
bowel, such as rectal bleeding or altered bowel habit; or the presence of ascites, leading to 
abdominal dissension; or some other general symptoms related to cancer, such as nausea, vomiting, 
anorexia, and cachexia (Edmondson & Todd, 2008).  However, because the symptoms often are 
not acute or intense and present vaguely, particularly in the early stages, most women are not 
diagnosed until the disease had been progressed to the advanced stage (National Ovarian Cancer 
Coalition, 2014a). 
When ovarian cancer is found early at a localized stage, about 94% of patients live longer than 
5 years after diagnosis (American Cancer Society, 2014a).  For women with high risks, such as 
those showing ovarian cancer symptoms, a strong family history, or a genetic predisposition, 
several screening tests are performed to help with diagnosis, including a complete pelvic exam, a 
transvaginal or pelvic ultrasound, or a CA-125 blood test (Ovarian Cancer National Alliance, 
2014b). However, screening tests for ovarian cancer are not recommended for general 
asymptomatic women by major medical and public health organizations including the U. S. 
Preventive Services Task Force (USPSTF), the American Congress of Obstetricians and 
Gynecologists, and the American Cancer Society (American Cancer Society, 2014a; Committee 
Opinion No. 477: The Role of The Obstetrician-Gynecologist in The Early Detection of Epithelial 
Ovarian Cancer, 2011; USPSTF, 2014a). The positive predictive value (PPV) of screening for 
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ovarian cancer is low due to the low prevalence of the diseases (with an age-adjusted incidence of 
13 cases per 100,000 women), as a result, most women with a positive screening test result are 
false-positive (USPSTF, 2014a). According to the Health Technology Assessment’s review of 16 
cohort studies on ovarian cancer screening among asymptomatic, average-risk women, using 
annual ultrasound screening, only 0.6 percent of those recalled for abnormal results, and 3 percent 
underwent surgery, have cancer. The PPV for CA 125-based multimodal screening (CA 125 
followed by ultrasound if CA 125 levels are high) was estimated as 1 percent for initial recall and 
15 percent for surgery. An estimated 3 percent to 12 percent of screened women will be recalled 
for further testing and assessment, resulting in potential distress and anxiety to otherwise healthy 
women. Approximately 0.5 percent to 1 percent of women will suffer a significant complication 
because of surgery (USPSTF, 2014b). Besides the potential harms of unnecessary surgery or 
repeated testing, based on a randomized controlled trial of 78,216 women in the U.S. population, 
simultaneous screening with CA-125 and transvaginal ultrasound does not reduce ovarian cancer 
mortality (Buys, Partridge, Black, & et al., 2011).  
Although the aforementioned tests can improve ovarian cancer diagnosis among women with 
symptoms or high risks, when used individually, these tests are not definitive. Currently, the only 
definitive way for ovarian diagnose is through surgery and biopsy (Ovarian Cancer National 
Alliance, 2014b).  
Once diagnosed with ovarian cancer, the stage of a tumor can be determined during surgery. 
Depending on whether the cancer spreads outside the ovaries, ovarian cancer can be classified into 
four stages: from Stage I (early disease) to Stage IV (advance disease) (National Ovarian Cancer 
Coalition, 2014c). According to the type of cell from which the cancer starts, ovarian cancer is 
classified into three types: (1) surface Epithelium-cells covering the lining of the ovaries, (2) germ 
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cell-cells destined to form eggs, and (3) stromal cells releasing hormones and connecting the 
different structures of the ovaries (National Ovarian Cancer Coalition, 2014c). Epithelial ovarian 
tumor, which accounts for 90% of the ovarian neoplasms and 70% of all ovarian malignancies is 
further classified as serous (30-70%), endometrioid (10-20%), mucinous (5-20%), clear cell (3-
10%), and undifferentiated (1%) (Rosen et al., 2009).  
Treatment plan usually depends on the kind of ovarian cancer and how far it has spread (CDC, 
2014c). Currently, there are three types of ovarian cancer treatment: (1) surgery to remove the 
cancerous growth; (2) chemotherapy to deliver chemicals through the bloodstream to destroy 
cancer cells or stop them from growing both in and outside the ovaries, and (3) radiation therapy 
to use high-energy X-rays to kill cancer cells and shrink tumors. Chemotherapy is used in the 
majority of cases as a follow-up therapy to surgery, and radiation therapy is only rarely used in the 
treatment of ovarian cancer in the United States (National Ovarian Cancer Coalition, 2014b).  
 
Factor Influencing Ovarian Cancer Diagnosis, Treatment and Survival  
Literature suggests that multilevel factors can influence ovarian cancer diagnosis, treatment 
and survival outcomes.  
Individual-level Factors:  
Pathological Factors 
Ovarian cancer stage at diagnosis, histology type, and grade of disease have been found to be 
important prognostic factors for survival (Chan, et al., 2008; Holschneider & Berek, 2000; 
Tingulstad, Skjeldestad, Halvorsen, & Hagen, 2003). Based on the statistics from the National 
Cancer Institute, SEER Data 2004-2010, the relative 5-year survival rates by ovarian cancer stage 
are as follows: 90% for stage I, 70% for stage II, 39% for stage III, and 17% for stage IV (American 
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Cancer Society, 2014b). Based on a systematic review of ovarian cancer pathology and biology, 
the survival outcome also vary by ovarian cancer histology type. The 5-year survival rates are 20-
35% for serous type, 40-63% for endometrioid type, 40-69% for mucinous type, 35-50% for clear 
cell type, and 11-29% for undifferentiated type (Rosen, et al., 2009). Furthermore, the treatment 
plan also greatly depends on cancer pathology (National Ovarian Cancer Coalition, 2014b). Hence, 
pathological factors need to be controlled for in modeling ovarian cancer disparities. 
 Race/Ethnicity: 
Race/ethnicity is an important contributor to health disparities. A broad range of factors such 
as social, behavioral, nutritional, psychological, residential, occupational can lead to racial and 
ethnic disparities in health.  The interaction between biological factors and social/natural 
environmental factors could be complex. The reasons for racial disparities in health outcomes are 
multifactorial. Emerging studies suggest that the effects of unequal access to treatment have 
amplified racial disparities in survival from ovarian cancer (Chan et al., 2008; Terplan, et al., 2012; 
Terplan, Smith, & Temkin, 2009). 
Previous studies yield inconsistent results on racial/ethnic disparities in ovarian cancer 
diagnosis. For instance, a study based on 1995-2007 SEER Medicare-linked data showed black 
women were more likely to present with stage IV disease compared to white women (42.1% versus 
33.5%) (Howell et al., 2013). This result is consistent with another study based on earlier SEER 
data (1988-2001), suggesting a significantly higher proportion of African Americans diagnosed at 
stages III and IV disease compared to whites (74.8% versus 70.1%) (Chan, et al., 2008).  However, 
another study based on SEER-Medicare linked 1992-1999 data found the percentage of ovarian 
cancer late stage diagnose (stage III and IV) was slightly higher in whites than African Americans 
(71.6% versus 69.7%) (Du, et al., 2008). Furthermore, a case-control study based on data collected 
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in Illinois in 1994-1998 showed no significant difference in stage at diagnosis between African 
American and Caucasian women (Kim, Dolecek, & Davis, 2010).  
Emerging studies also indicate racial disparities in ovarian cancer treatment. For example, 
analysis of 1992-1999 SEER-Medicare linked data showed that compared with Caucasians, 
significantly lower percentage of African-Americans received chemotherapy for ovarian cancer 
treatment (Du, et al., 2008). According to a meta-analysis, white women are 1.17 times more likely 
to receive any form of surgical treatment for ovarian cancer than African Americans (Terplan, et 
al., 2009).   
Although ovarian cancer mortality rates are slightly higher for white women than for African-
American women (Ovarian Cancer National Alliance, 2013), one study suggests that the 5-year 
disease-specific survival of whites is significantly higher (44.1% versus 40.7%) than African-
Americans (Chan, et al., 2008). According to an analysis of the SEER 1973-2008 database the 
disparities in ovarian cancer survival outcome has increased over the past three decades (Terplan, 
et al., 2012). However, an earlier study based on the 1992-1999 SEER data found no significant 
racial disparities in survival outcome between African-American and Caucasian women after 
adjusting for tumor characteristics, treatment, and socio-demographic factors (Du, Sun, Milam, 
Bodurka, & Fang, 2008).   
When examining racial disparities in ovarian cancer diagnosis, treatment, and survival 
outcomes, most previous studies mainly focused on comparison between African American and 
Caucasian subpopulations. Very few studies included Hispanics, the largest and fastest growing 
minority ethnic group in the U.S. One study based on the 2000-2004 SEER data indicated that 
compared to non-Hispanic whites (NHWs) and non-Hispanic blacks (NHBs), Hispanic women 
were more likely to be diagnosed with ovarian cancer at a younger age and earlier stage, and had 
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a statistically significantly longer median survival (Ibeanu & Diaz-Montes, 2013). However, given 
the rapid growth of Hispanic population, especially in rural areas and small town (The Housing 
Assistance Council, 2012), it remains unknown whether Hispanic patients still have better survival 
outcomes than NHWs and NHBs.  
  Age 
Age can also contribute to health disparities. Poorer prognosis and worse health outcomes 
among older persons may be attributed to several reasons. First, financial concerns might be one 
of the barriers to accessing needed healthcare services, because the majority of elderly population 
lives on fixed income and may not be able to cover their unanticipated healthcare costs. Second, 
increasing risks of comorbidities and complications may inhibit elderly to choose or adhere to 
required invasive therapies such as surgery and chemotherapy. Thirdly, they may also face some 
physical challenges (e.g., due to impaired mobility, disordered cognition, or lack of transportation) 
for accessing or asking for necessary healthcare services. Additionally, compared to younger 
population, older people may have fewer opportunities to access necessary health information via 
different media channels, such as Internet. Thus, older people are at a disadvantage in terms of 
accessing health related information in order to identify symptoms and to seek appropriate 
healthcare services. 
Regarding ovarian cancer disparities by age, the receipt of cancer treatment is influenced by 
patients’ age. For example, based on 2005 Australian Cancer Registries records, increasing age is 
associated with non-receipt of chemotherapy, and one possible explanation is that older women 
may have higher rates of toxicity with chemotherapy compared with younger women (Jordan et 
al., 2013). A retrospective cohort study conducted in Denmark in 2005-2006, found that compared 
with patients less than 70 years, elderly patients were also less likely to receive primary surgery 
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(Jørgensen et al., 2012).  Based on an analysis of the 1988-2001 SEER data, compared with older 
ovarian cancer patients (i.e. those aged > 60 years), younger patients (i.e. those aged < 30 years) 
had a significantly higher 5-year cancer survival rate (78.8% versus 35.3%), and this survival 
advantage remained even after adjusting for race, stage, grade, and surgical treatment (Chan et al., 
2006). In another study based on a statewide Maryland hospital discharge data, no significant 
differences in the number of comorbidities and intensive care unit length of stay were found 
between women aged over 80 years and their younger counterparts. However, the 30-day mortality 
rate was found to be 2.3 times higher for the older group compared with the younger group (Díaz-
Montes et al., 2005). 
  Insurance Status 
Insurance status is another important contributor to ovarian cancer disparities. Lack of health 
insurance has long been linked to negative outcomes for many diseases.  According to a study of 
cancer outcomes based on the National Cancer Database with records from 12 sites, patients who 
were uninsured or had Medicaid insurance were diagnosed with more advanced disease than 
privately insured patients (Halpern et al., 2008). In another study, patients from counties with lower 
uninsured rates had longer median survival, and county uninsured rate was also associated with 
the stage at diagnosis for all cancers (Smith et al., 2013).  
Additionally, there is a difference in insurance status by race/ethnicity. Compared to white 
ovarian cancer patients, African-American patients were more likely to have Federal payer status 
(Medicaid or Medicare) and less likely to have commercial insurance payer status (Bristow, 
Zahurak, & Ibeanu, 2011). Previous studies also reported higher mortality for Medicare and 
Medicaid patients compared to privately insured patients (LaPar et al., 2010).  According to the 
2012 NHIS data, Hispanic persons aged less than 65 years (32%) were more than twice as likely 
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as non-Hispanic persons in the same group (14%) to be uninsured (CDC, 2014).  
However, despite the association between insurance status and race/ethnicity, to what extent 
the insurance status can contribute to the racial disparities in ovarian cancer remains unknown. For 
instance, based on the 1998-2004 US National Cancer Database, for general cancer patients, 
irrespective of insurance status, black and Hispanic patients had an increased risk of advanced 
stage disease (stages III or IV) at diagnosis (Halpern, et al., 2008). While in another study, public 
insurance was found to be associated with an increased hazard of ovarian cancer mortality and 
disease recurrence independent of race (Mishka Terplan, Temkin, Tergas, & Lengyel, 2008).  
  Marital Status 
Being married has long be linked with improved health status and decreased mortality 
(Johnson, Backlund, Sorlie, & Loveless, 2000; Sorlie, Backlund, & Keller, 1995). According to a 
study focusing on the impact of marital status on cancer outcomes, based on the 2004-2008 SEER 
data, for cancer patients of the top 10 lethal cancer diseases (including ovarian cancer), unmarried 
patients were at significantly higher risk of presentation with metastatic cancer, undertreatment, 
and death resulting from their cancer (Aizer et al., 2013).   
Few studies have reported the effect of marital status on ovarian cancer disparities in diagnosis, 
treatment and survival outcomes. A study based on 1988-2006 SEER data indicated that being 
married was independently associated with improved survival in women with ovarian cancer, with 
adjustment for race, age, histology, stage, grade, and surgical treatment (Mahdi et al., 2013). 
However, it is uncertain whether the effects remain after controlling for socioeconomic 
environment.  
 
 
21 
 
Contextual-level Factors  
 Rural/Urban Residence 
The population in rural and small town America increased by roughly 3.5 million between 
2000 and 2010. More than half of all rural and small town population growth in the last decade is 
attributable to Hispanics. In rural and small town areas, the Hispanic population increased by 1.9 
million or 46 percent between 2000 and 2010, surpassing African Americans (8.2 percent) as the 
largest minority group in rural and small town areas (The Housing Assistance Council, 2012).  
With the rapid increase of minority population in rural areas, it is important to analyze the 
rural-urban and racial patterns in ovarian cancer disparity. Such analysis allows us to quantify and 
potentially reduce ovarian cancer-related health disparities between the least and most burdened 
subpopulations.  
The rural/urban disparity in health may be related to different lifestyles leading to different 
levels of exposure to risk factors, unequal access to healthcare services, and different quality of 
healthcare services and availability of the diagnostic tools and treatment required. Compared with 
people who live in urban areas, people who live in rural areas may have lower accessibility to 
health care and face longer travel times and lower access to specialized care (Chan, Hart, & 
Goodman, 2006). 
Previous research yield inconsistent results on influence of rural and urban residence on 
ovarian cancer outcomes. A study conducted in Poznan, Poland during 2004-2011, suggest urban 
disadvantage. According to this study, compared with women who live in small towns and rural 
areas, several ovarian cancer risk factors, such as lower median parity and experienced menarche 
at an earlier age, were found to be more common among women in large cities. However, no 
rural/urban differences in stage at diagnosis or tumor type and size were found (Szpurek, 
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Moszynski, Szubert, & Sajdak, 2013). Several other studies suggested opposite results. One study 
in Denmark found greater risk of long diagnostic delays in rural areas (Robinson, Christensen, 
Ottesen, & Krasnik, 2011); and a study conducted in Australia suggested that rural residence was 
associated with non-receipt of chemotherapy (Jordan, et al., 2013). None of the studies to date 
have focused on ovarian cancer disparities by rural/urban residence in the U.S. 
  Socioeconomic Status 
Socioeconomic Status (SES) is defined as a composite measure that typically incorporates 
economic, social, and work status. Economic status is measured by income. Social status is 
measured by education, and work status is measured by occupation (CDC, 2014a). Individual-
level socioeconomic status has long be associated with disparities in health outcomes and 
healthcare accessibility. For example, a person with more education is more likely to get a well-
paid job and have health insurance, and people who have higher incomes and health insurance are 
more likely to get preventive services and the right treatment (CDC, 2014b). However, emerging 
studies suggest the independent effects of contextual-level (such as county-level and community- 
level) socioeconomic status on health disparity. This may imply that the higher contextual-level 
SES can confer risk of diseases and reduce healthcare accessibility regardless of individuals’ own 
SES. For instance, according to a longitudinal survey based on nationally representative 
households sampling, living in disadvantaged neighborhood (characterized as high percentage of 
residents below poverty line, high percentage of unemployment, and high percentage of residents 
with no high school diploma or GED) reduced the likelihood of having a usual source of care and 
increased the likelihood of having unmet medical need. This association remained to be 
statistically significant after controlling for individual-level characteristics (Kirby & Kaneda, 
2005). According to a longitudinal study conducted in Netherlands, living in a neighborhood with 
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a high percentage of unemployed/disabled or poor persons was associated with increased mortality, 
and the effects remained even after controlling for individual socioeconomic status (Bosma, van 
de Mheen, Borsboom, & Mackenbach, 2001).  
As it relates to cancer, based on an analysis using SEER 1975-2000 data, for several major 
types of cancers combined (but not including ovarian cancer), residents of poorer counties (with 
greater or equal to 20% of the population below the poverty line) had higher age-adjusted death 
rate and lower 5-year survival rate compared with more affluent counties (Ward et al., 2004). The 
contextual effect of SES on disparities in breast cancer and cervical cancer have been well 
established (Breen & Figueroa, 1996; Coughlin, et al., 2008; Robert et al., 2004). However, few 
studies focused on the association between contextual-level SES and ovarian cancer disparities in 
diagnosis, treatment, and survival outcomes. Furthermore, based on systematic review of previous 
studies, the pattern of association between cancer mortality and SES (measured at individual or 
contextual levels) may vary for specific cancers (Singh, Williams, Siahpush, & Mulhollen, 2012). 
For instance, higher SES was found to be associated with lower rates of lung, stomach, cervical, 
esophageal, oropharyngeal, and liver cancer mortality and higher rates of breast cancer and 
melanoma (Singh, et al., 2012). As a result, it remains uncertain whether high contextual-level SES 
has positive effect on ovarian cancer diagnosis, treatment, and survival.  
To the best of my knowledge, racial/ethnic disparities in ovarian cancer diagnosis, 
treatment and survival outcome using up to date national level cancer registry data have not been 
examined. It also remains uncertain whether racial/ethnic disparities in ovarian cancer have 
changed over the last decade. There is lack of studies focusing on contribution of both individual- 
and contextual-level factors on ovarian cancer disparities. Previous studies have produced 
inconsistent results on the association of the aforementioned factors with ovarian cancer outcomes. 
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Findings from the current study will narrow the gap in ovarian cancer research by identifying 
social factors and mechanisms contributing to disparities in health care access and health outcomes. 
By identifying the subpopulations which suffer an excessive ovarian cancer burden, the study may 
provide insights on how to modify currently existing health policies (e.g., on medical resource 
allocation and public insurance reimbursement and coverage) and to develop health promotion 
programs specifically targeting hard-to-reach populations (e.g., women living in disadvantaged 
neighborhoods or minority groups with language barriers).  
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CHAPTER 3 
 
METHODOLOGY 
 
Study Design 
 
This was an observational, retrospective, cross-sectional study of a population-based 
cancer registry database. Demographic, pathological, diagnosis, treatment, and survival 
information from women diagnosed with malignant ovarian cancer from 2001 to 2012 was 
extracted from the SEER Program of the National Cancer Institute (NCI). Patients diagnosed 
before age of 18, had a prior malignancy, and those not diagnosed with microscopic confirmation 
or have unknown diagnostic confirmation were excluded. The information obtained was not 
individually identifiable, and as a result, the study was exempt from the Georgia Southern 
Institutional Review Board approval.  
 
Secondary Data Source 
 
The SEER program collects cancer incidence and survival data from 18 population-based 
cancer registries that represent approximately 27.8% of the U.S. population and is a premier 
source for cancer statistics in the United States (National Cancer Institute, 2015e). The 
geographic areas (registries) which are covered include San Francisco-Oakland SMSA, 
Connecticut, Detroit (Metropolitan), Hawaii, Iowa, New Mexico, Seattle (Puget Sound), Utah, 
Atlanta (Metropolitan), San Jose-Monterey, Los Angeles, Alaska Natives, Rural Georgia, 
California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Greater Georgia 
(National Cancer Institute, 2015e). The SEER 18 Regs Research data include adjustments for 
areas impacted by hurricanes Katrina and Rita (National Cancer Institute, 2015e). United States 
Census 2000 and 2007-2011 data were used for county-level SES variables (US Census Bureau 
2007-2011).  
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Study Variables  
Main outcome variables included the stage of ovarian cancer at diagnosis, receipt of 
surgery treatment, and survival time. The stage of ovarian cancer at diagnosis was classified 
according to the American Joint Committee on Cancer classification system as stage 0 (in situ), I 
(cancer is limited to the ovary or ovaries), II (growth of the cancer involves one or both ovaries 
with pelvic extension), III (the cancer has spread beyond the pelvis to the lining of the abdomen 
or the cancer has spread to lymph nodes), IV (the cancer has spread to organs located outside of 
the peritoneal cavity) (National Cancer Institute, 2013). For the purposes of this study, the stage 
of diagnosis was further dichotomized into non-advanced stage (stages 0, I, II) and advanced 
stage (stages III and IV). Surgery treatment information was measured as receipt of surgery 
(yes/no). The event in the time-to-event/survival analyses was ovarian cancer-cause specific 
death within 5 years since ovarian cancer diagnosis, and survival time was defined as the time 
from the time of ovarian cancer diagnosis till the ovarian cancer-cause specific death or the 
cutoff time for follow-up (Dec 31, 2012). Ovarian cancer patients who died of other causes, or 
died of ovarian cancer but after more than 5 years since ovarian cancer diagnosis were treated as 
censored cases. The survival outcome was measured as 5-year ovarian cancer-cause specific 
mortality and reported as Hazard Ratio (HR).  
 Other individual-level factors obtained from SEER included age at diagnosis which was 
categorized into five categories (18-45 years/46-55 years/56-65 years/66-75 years/older than 76 
years), race/ethnicity (NHW/ NHB/Hispanic/Other), marital status (married/not married), 
insurance status (insured/ uninsured) and tumor pathological characteristics. According to the 
International Classification of Diseases O-2 codes, tumor grade providing clinic-pathologic 
information, was classified as well- differentiated, moderately differentiated, poorly 
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differentiated, undifferentiated and unknown (National Cancer Institute, 2013). Major histology 
types were classified as clear cell, mucinous, serous, endometrioid, other, or not otherwise 
specified (NOS), based on the International Classification of Diseases O-3 codes.  
Contextual-level variables included residence in a metro/nonmetro county and county-
level SES status. According to the rural-urban continuum code (RUCC) classification system 
(United States Department of Agriculture, 2013), counties were classified as metro or nonmetro, 
using the Federal Information Processing Standards [FIPS] codes. Based on the RUCC 
classification system, counties with RUCC codes ≤ 3 (counties in metro areas of fewer than 
250,000 population, 250,000 population or more) were defined as metro counties, and counties 
with RUCC codes 4-9 (counties adjacent or not adjacent to a metro area and with urban population 
of 2,500 or more or with completely rural or less than 2,500 urban population) were defined as 
nonmetro counties (United States Department of Agriculture, 2013). County-level SES variables 
included education, employment and poverty level. They were accessed through the SEER*Stat 
Datasets measured at ratio level, and were calculated based on 2000 Census Data and 2007-
2011Census American Community Survey (ACS) 5-year files (National Cancer Institute, 
2015c).The county-level Census data were matched with the individual-level SEER data by county 
FIPS codes. Patients diagnosed from the year of 2000-2006 were matched with the 2000 census 
data, and those diagnosed from the year of 2007-2011 were matched with the 2007-2011 census 
data. The county-level SES measurements include county education (i.e. percentage of a county 
population with less than 9th grade education); county employment (i.e. percentage of persons 
aged 16 and over who are unemployed in a county), and county poverty (i.e. percentage of persons 
in a county whose incomes are below the 100% federal poverty level threshold (U.S. Department 
of Health & Human Services, 2013). Each of these county SES percentage measures were sorted 
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and categorized into quartiles (highest/upper-middle/lower-middle/lowest) when included into 
models for analysis.  For each of the three county SES quartile measures, counties in a higher 
quartile have a superior county level SES. Collinearity among contextual-level factors was 
assessed, its lack was confirmed with VIFs < 2.5.  
 
Data Analysis 
 
All individual- and contextual-level data were extracted using the 8.2.1 SEER*Stat 
Software (National Cancer Institute, 2015f). Statistical analyses were performed using the Stata 
SE 14.0 statistical software (College Station, TX) and Joinpoint trend analysis software version 
4.2.0.1. (National Cancer Institute, 2015d). Descriptive statistics were used to describe the 
distribution of individual-level socio demographic and tumor pathological characteristics, and 
contextual-level factors. X-square tests of independence and analysis of variance (ANOVA) 
were applied to assess the difference in distribution of each of these characteristics among 
selected cases by race/ethnicity.  
Multilevel binary logistic regression analyses were used to assess the effect of race and 
ethnicity on stage diagnosis and receipt of surgery adjusted for individual-level and county-level 
variables. Models included a random intercept for a county of residence; while the rest of the 
variables were included as fixed effect. To identify factors contribute to the racial/ethnic 
disparities, sub analysis using multilevel binary logistic regression were then conducted stratified 
by race/ethnicity subgroups (NHW, NHB, and Hispanic). Average predicted margins and 
marginal effects were calculated from multilevel logistic regression analysis with adjustment for 
random effect and interaction effect. Adjusted probability estimates for advanced stage diagnosis 
and receipt of surgery treatment were reported based on each of the logistic regressions.  
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The Cox proportional hazards model with shared frailty (i.e. multilevel model) was used 
to assess racial/ethnic disparities in ovarian cancer-cause specific mortality and to identify 
factors contributing to the disparities. The proportional hazards assumption was assessed by 
graphing the scaled Schoenfeld residuals on function of time, and testing the significance of 
interaction between the variables of interest and time.  
Because insurance status information was only available for patients diagnosed in and 
after 2007, when insurance status was added into each of the logistic regression and Cox 
proportional hazards models, only cases diagnosed in 2007 and later were included in the 
analyses. For all the logistic regression and Cox proportional hazards models, significance of 
interaction terms between race/ethnicity and variables of interest were checked, and significant 
interaction terms were included in the final models.  
To test whether the racial/ethnic disparities in stage at diagnosis, receipt of surgery 
treatment and ovarian cancer-cause specific mortality have changed over time, cases were 
grouped into 12 cohorts by year of diagnosis, and for each of the cohorts, logistic regressions 
were used to estimate odds ratios for advanced stage diagnosis and receipt of surgery, and 
survival analysis was used to estimate hazard ratios for ovarian cancer cause-specific death. The 
odds ratios and hazard ratios were estimated comparing each of the two racial/ethnic groups 
(NHW vs. NHB, NHW vs. Hispanics, and NHB vs. Hispanics), while adjusting for individual- 
and contextual-level confounders. The estimated odds ratios and hazard ratios for the 12 cohorts 
were then analyzed using the Joinpoint trend analysis software. This software takes trend data 
(odds ratios and hazard ratios) as dependent variables, year of diagnosis as independent variable, 
and fits the simplest Joinpoint model that the data allow. This analysis was applied to test 
whether an apparent change in trend was statistically significant. The test of significance applies 
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a Monte Carlo Permutation method (National Cancer Institute, 2015d). All tests were two-tailed. 
A significant level was set at P <0.05. 
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CHAPTER 4 
RESULTS 
Descriptive Characteristics 
 There were 69,444 women diagnosed with malignant ovarian cancer between 2001 and 
2012. Among those ovarian cancer patients, 669 cases were excluded because of age (less than 
18 years old at diagnosis); 5,316 cases were excluded because of having no microscopic or 
unknown diagnostic confirmation; 8,686 cases were excluded because of prior malignancy 
diagnosis, and 193 cases were eliminated due to unknown race/ethnicity status. The final study 
sample included 54,580 ovarian cancer patients, of whom 39,726 (72.78%) were NHWs, 4,295 
(7.87%) were NHBs, 6,256 (11.46%) were Hispanic, and 4,303 (7.88%) were of other 
race/ethnicity (e.g. American Indian/Alaska Native and Asian or Pacific Islander).  
 Descriptive characteristics are presented in Table 1 by race/ethnicity. NHW patients were 
diagnosed at an older age (mean age=62.55, p<0.001)) compared with NHBs (mean age=59.57), 
Hispanics (mean age=55.63) and patients of other race/ethnicity (mean age=55.88). The 
prevalence of ovarian cancer by groups of age at diagnosis also significantly varied across 
race/ethnicity groups (p<0.001). NHW (25.06%) and NHB (24.05%) patients were more likely to 
be diagnosed at age of 55-64 compared with other age groups, but Hispanics were more likely to 
be diagnosed at the age of 18-45 (25.69%). NHW (54.24%) patients had a larger proportion of 
married women compared with NHBs (31.18%) and Hispanics (49.30%), but the proportion of 
being married was the highest in patients from Other racial/ethnic groups (58.62%) (p<0.001). 
NHW patients had the highest health insurance coverage rate (96.80%), followed by patients 
from Other racial/ethnic groups (95.36%), NHB (92.83%) and Hispanic patients (90.44%) 
(p<0.001). NHB patients (72.60%) were more likely to be diagnosed at advanced stage compared 
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with patients from NHW (71.29%), Hispanic (66.66%), and Other racial/ethnic groups (61.10%) 
(p<0.001). Patients from Other racial/ethnic groups (85.65%) had the highest rate of receiving 
surgery treatment, followed by Hispanics (82.29%), NHW (81.63%), and NHBs (69.18%) had 
the lowest rate for surgery treatment (p<0.001). Regarding tumor pathological characteristics, the 
prevalence of tumor grade and histology also significantly varied by race/ethnicity (p<0.001).  
 In terms of contextual-level characteristics, higher percentage of NHW patients (13.10%) 
lived in nonmetro areas compared to patients in NHB (9.39%), Hispanic (3.96%) and Other 
racial/ethnic groups (5.06%) (p<0.001). More Hispanic patients (48.91%) lived in counties with 
lowest quartile rank of county-level education compared to patients in NHW (19.54%), NHB 
(21.86%), and Other racial/ethnic groups (27.96%) (p<0.001). NHB patients were more likely to 
live in counties characterized as lowest SES when measured by unemployment (NHB: 37.81%, 
NHW: 18.72%, Hispanic: 24.34%, other: 12.53, p<0.001) and poverty rate (NHB: 35.51%, NHW 
19.58%, Hispanic: 28.23%, other: 15.64%, p<0.001).  
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Table 1  
Characteristics of Ovarian Cancer Cases, 2001-2012, SEER (N=54,580) 
Characteristics Non-Hispanic 
White 
(n=39,726) 
%a 
Non-Hispanic 
Black 
(n=4,295) 
% 
Hispanic 
 
(n=6,256) 
% 
Other 
 
(n=4,303) 
% 
p-value 
Age at diagnosis 
(mean) 
62.55 59.57 55.63 55.88 <0.001 
Age at diagnosis 
(Group) 
    <0.001 
    18-45 11.37 17.88 25.69 23.66  
    45-54 20.22 20.58 23.91 27.70  
    55-64 25.06 24.05 21.44 22.08  
    65-74 21.63 20.88 17.04 14.85  
    >=74 21.73 16.60 11.92 11.71  
Marital status     <0.001 
    Not married 45.76 68.82 50.70 41.38  
    Married 54.24 31.18 49.30 58.62  
Insurance b      <0.001 
    Uninsured 3.20 7.17 9.56 4.64  
    Insured 96.80 92.83 90.44 95.36  
      
Stage     <0.001 
    Non-advanced 28.71 27.40 33.34 38.90  
    Advanced 71.29 72.60 66.66 61.10  
Surgery      
    No  18.37 30.82 17.71 14.35 <0.001 
    Yes 81.63 69.18 82.29 85.65  
Grade      <0.001 
    Well differentiated 6.60 5.77 8.07 7.81  
    Moderately 
differentiated 
13.42 11.06 13.16 14.06  
    Poorly differentiated 34.29 29.29 30.66 33.07  
    Undifferentiated 12.97 8.87 10.55 13.15  
    Unknown 32.72 45.01 37.56 31.91  
Histology      <0.001 
    Serous 46.19 37.30 36.69 35.77  
    Mucinous 5.48 6.38 7.18 7.90  
    Endometrioid 9.59 6.10 10.10 11.85  
    Clear cell 5.14 2.51 4.51 11.71  
Other or unspecified 33.60 47.71 38.52 32.77  
      
Contextual-level 
Factors 
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Characteristics Non-Hispanic 
White 
(n=39,726) 
%a 
Non-Hispanic 
Black 
(n=4,295) 
% 
Hispanic 
 
(n=6,256) 
% 
Other 
 
(n=4,303) 
% 
p-value 
Metro/nonmetro 
Residence c 
    <0.001 
    Metro 86.90 90.61 96.04 94.94  
    Nonmetro 13.10 9.39 3.96 5.06  
County education d     <0.001 
    Highest 30.12 16.07 7.24 13.87  
    Upper-middle 26.35 37.46 13.63 19.38  
    Lower-middle 23.98 24.61 30.21 38.79  
    Lowest 19.54 21.86 48.91 27.96  
County employment e     <0.001 
    Highest 29.58 14.41 12.18 26.63  
    Upper-middle 25.87 17.63 20.46 23.38  
    Lower-middle 25.83 30.15 43.01 37.46  
    Lowest 18.72 37.81 24.34 12.53  
County poverty f     <0.001 
    Highest 28.20 13.13 13.20 27.28  
    Upper-middle 27.11 17.97 19.17 33.35  
    Lower-middle 25.10 33.39 39.40 23.73  
    Lowest 19.58 35.51 28.23 15.64  
Notes: a Unadjusted percentage b Only for cases diagnosed in 2007 and after. c Metro vs. nonmetro categories are based 
on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S. 
Department of Agriculture. d Sorted by percentage of a county population with less than 9th grade education in 
ascending order, and categorized into quartiles.  e Sorted by percentage of persons aged 16 and over who are 
unemployed in a county in ascending order, and categorized into quartiles. f Sorted by percentage of persons in a 
county whose incomes are below the 100% federal poverty level threshold in ascending order, and categorized into 
quartiles.  
 
 
Advanced Stage Diagnosis 
 Racial/Ethnic Disparities in Advanced Stage Diagnosis 
 As shown in Table 2 (Odds Ratios are presented in Appendix F: Table 2.2), adjusting for 
all the variables listed in Table 1, year of diagnosis, county random effect, and interaction effect 
of race/ethnicity and county-level employment, significant racial/ethnic disparities in advanced 
stage diagnosis only exist in counties with county-level employment rate ranked in the highest 
35 
 
and lower-middle quartiles. Significant differences in advanced stage diagnosis between NHB 
and NHW patients were only observed in counties with the employment rate ranked in the 
highest quartile, and in such counties, NHB patients (75.44%, 95%CI: 72.35% – 78.53%) were 
significantly more likely to present with advanced ovarian cancer at the time of diagnosis 
compared to NHW patients (69.52%, 95%CI: 68.58% - 70.46%). For patients living in counties 
that ranked in lower-middle quartile for employment rate, patients from Other racial/ethnic 
groups (66.91%, 95%CI: 64.80% - 69.01%) had significantly lower probability of advanced 
stage diagnosis compared with their NHW counterparts (70.65%, 95%CI: 69.76% - 71.54%). 
The prevalence of advanced stage diagnosis among Hispanic patients did not significantly differ 
from the prevalence in NHW patients.  
 
 
Table 2  
Adjusted Prevalence of Advanced Stage Diagnosis and Receipt of Surgery a  
Study Variables Advanced Stage Diagnosis 
(N=54,580) 
% b (95%CI ) 
Receipt of Surgery 
(N=54,580) 
% b (95%CI ) 
Race/ethnicity   
    Non-Hispanic White – 83.40 (83.04 – 83.76) ref 
    Non-Hispanic Black – 77.65 (76.73 – 78.58)* 
    Hispanic – 81.96 (81.16 – 82.76)* 
    Other – 81.94 (80.92 – 82.97)* 
Age at diagnosis   
    18-45 55.73 (54.64 – 56.83) ref 93.81 (93.20 – 94.41) ref 
    46-55 65.85 (65.01 – 66.69)* 88.79 (88.16 – 89.42)* 
    56-65 71.94 (71.18 – 72.69)* 85.26 (84.68 – 85.84)* 
    66-75 75.77 (74.97 – 76.57)* 81.51 (80.88 – 82.13)* 
    >=76 79.41 (78.60 – 80.22)* 71.86 (71.11 – 72.62)* 
Marital status   
    Not married 70.70 (70.15 – 71.26) ref 81.13 (80.70 – 81.56) ref 
    Married 69.81 (69.28 – 70.33)* 84.31 (83.89 – 84.72)* 
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Study Variables Advanced Stage Diagnosis 
(N=54,580) 
% b (95%CI ) 
Receipt of Surgery 
(N=54,580) 
% b (95%CI ) 
Stage   
    Non-advanced – 94.29 (93.84 – 94.74) ref 
    Advanced – 79.32 (78.88 – 79.75)* 
Grade    
    Well differentiated 43.97 (42.21 – 45.74) ref 91.91 (90.34 – 93.47) ref 
    Moderately differentiated 60.95 (59.84 – 62.06)* 92.59 (91.78 – 93.40)* 
    Poorly differentiated 74.85 (74.19 – 75.50)* 91.93 (91.50 – 92.37)* 
    Undifferentiated 73.93 (72.85 – 75.00)* 94.21 (93.60 – 94.83)* 
    Unknown 73.88 (73.21 – 74.56)* 68.57 (67.83 – 69.32)* 
Histology    
    Serous 82.57 (82.04 – 83.09) ref 89.40 (88.98 – 89.83) ref 
    Mucinous 51.69 (49.84 – 53.55)* 84.11 (82.78 – 85.45)* 
    Endometrioid 46.12 (44.61 – 47.62)* 92.00 (90.70 – 93.29)* 
    Clear cell 39.93 (38.16 – 41.69)* 92.83 (91.64 – 94.03)* 
    Other or unspecified 69.70 (68.96 – 70.43)* 74.02 (73.40 – 74.64)* 
   
Interaction: race/ethnicity * 
county employment   
County employment: highest   
    Non-Hispanic White 69.52 (68.58 – 70.46) ref – 
    Non-Hispanic Black 75.44 (72.35 – 78.53)* – 
    Hispanic 67.82 (64.75 – 70.88) – 
    Other 71.28 (68.84 – 73.72) – 
County employment: upper-
middle   
    Non-Hispanic White 70.52 (69.63 – 71.40) ref – 
    Non-Hispanic Black 72.22 (69.34 – 75.11) – 
    Hispanic 70.64 (68.39 – 72.90) – 
    Other 69.29 (66.71 – 71.86) – 
County employment: lower-
middle   
    Non-Hispanic White 70.65 (69.76 – 71.54) ref – 
    Non-Hispanic Black 71.33 (69.06 – 73.61) – 
    Hispanic 71.13 (69.51 – 72.76) – 
    Other 66.91 (64.80 – 69.01)* – 
County employment: lowest   
    Non-Hispanic White 69.91 (68.76 – 71.06) ref – 
    Non-Hispanic Black 70.55 (68.37 – 72.73) – 
    Hispanic 70.83 (68.67 – 73.00) – 
    Other 69.71 (66.10 – 73.31) – 
   
Contextual-level factors:   
Metro/nonmetro residence c   
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Study Variables Advanced Stage Diagnosis 
(N=54,580) 
% b (95%CI ) 
Receipt of Surgery 
(N=54,580) 
% b (95%CI ) 
    Metro 70.27 (69.84 – 70.70) ref 82.66 (82.29 – 83.02) ref 
    Nonmetro 69.88 (68.73 – 71.02) 82.16 (81.37 – 82.95) 
County education d   
    Highest 70.91 (69.98 – 71.83) ref 82.50 (81.77 – 83.23) ref 
    Upper-middle 69.90 (69.06 – 70.73) 82.76 (82.11 – 83.41) 
    Lower-middle 70.41 (69.59 – 71.22) 82.40 (81.70 – 83.11) 
    Lowest 69.67 (68.72 – 70.62) 82.73 (82.06 – 83.40) 
County employment e   
    Highest – 82.80 (82.15 – 83.46) ref 
    Upper-middle – 82.74 (82.11 – 83.37) 
    Lower-middle – 82.78 (82.22 – 83.34) 
    Lowest – 81.98 (81.21 – 82.74) 
County poverty f   
    Highest 69.00 (67.96 – 70.04) ref 83.17 (82.35 – 84.00) ref 
    Upper-middle 69.72 (68.85 – 70.58) 82.41 (81.70 – 83.13) 
    Lower-middle 70.93 (70.12 – 71.75)* 82.50 (81.88 – 83.11) 
    Lowest 71.34 (70.37 – 72.30)* 82.34 (81.65 – 83.04) 
   
Random effect   
County variance 0.0070 
 
0.0451* 
Notes: a Adjusted for all the variables listed in the table, year of diagnosis, interactions between race/ethnicity and 
county employment, and county random effects. b Average adjusted predicted probabilities. c Metro vs. nonmetro 
categories are based on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research 
Service, U.S. Department of Agriculture. d Sorted by percentage of a county population with less than 9th grade 
education in ascending order, and categorized into quartiles.  e Sorted by percentage of persons aged 16 and over who 
are unemployed in a county in ascending order, and categorized into quartiles. f Sorted by percentage of persons in a 
county whose incomes are below the 100% federal poverty level threshold in ascending order, and categorized into 
quartiles. 
CI, confidence interval.  ref reference group. * p<0.05 
 
 
 Factors Associated with Disparities in Advanced Stage Diagnosis 
 Based on adjusted analysis, the probability of advanced stage diagnosis significantly 
increased by age. On average, women being diagnosed at the ages of 76 or older  had a 23.68% 
increased probability of being diagnosed at advanced stage compared to women being diagnosed 
between  the ages of 18 to 45 (p<0.05). On average, a significantly smaller percentage of married 
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women (69.81%, 95%CI: 69.28% - 70.33%) were diagnosed at advanced stage compared to 
unmarried women (70.70%, 95%CI: 70.15% - 71.26%) (p<0.05). 
 With respect to contextual-level factors, although not statistically significant, patients 
living in nonmetro counties (69.88%, %95CI: 68.73% – 71.02%) had lower probability of being 
diagnosed at advanced stage, compared to patients living in metro counties (70.27%, 95%CI: 
69.84% – 70.70%). The average probability of advanced stage diagnosis also did not 
significantly vary by county-level education. Interaction between race/ethnicity and county-level 
employment was found to be significantly associated with advanced stage diagnosis. The effect 
of county-level employment rate varied by race/ethnicity.  When considering the county-level 
poverty status, patients from the lower-middle (70.93%, 95%CI: 70.12% – 71.75%) and lowest 
quartile counties (71.34%, 95%CI: 70.37% – 72.30%) had a significantly increased probability 
of advanced stage diagnosis compared to patients from the highest quartile counties (69.00%, 
95%CI: 67.96% – 70.04%).  Based on the results of a sub analysis, when adding insurance status 
to the original model, and only including cases diagnosed in 2007-2012, on average, the 
probability of advanced stage diagnosis did not significantly differ by insurance status 
(uninsured: 69.24% vs. insured: 68.74%) (Appendix A: Table 2.1). The average probability of 
advanced stage diagnosis also did not vary significantly across counties (variance: 0.0068, 
p=1.0000). However, when comparing model (results not shown) adjusted for individual-level 
factors only with the full model (i.e., the one with both individual- and contextual-level factors), 
county random effect (variance) decreased from 0.0087 to 0.0068. 
 Factors Contributing to Racial/Ethnic Disparities in Advanced Stage Diagnosis 
 Results based on the sub analysis stratified by race/ethnicity group are shown in Table 3 
(Odds Ratios are presented in Appendix G: Table 3.2).  Age at diagnosis was positively 
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associated with advanced stage diagnosis for patients in all three racial/ethnic groups. The 
association between marital status and advanced stage diagnosis was statistically significant for 
NHW patients (married: 71.04% vs. unmarried: 72.00%, p<0.05), but not for NHB and Hispanic 
patients. Insurance status was not significantly associated with advanced stage diagnosis for 
patients in either of the three groups (Appendix B: Table 3.1). For patients in all three groups, 
probability of being diagnosed at advanced stage did not significantly vary by metro/nonmetro 
residence or county-level education status. County-level employment was significantly 
associated with advanced stage diagnosis in NHB patients, but not in NHW and Hispanic 
patients. NHB patients from counties with employment rate ranked in the lower-middle (72.19%, 
95%CI: 69.63% – 74.75%) and lowest quartiles (70.93, 95%CI: 68.41% – 73.45%) had a 
significantly lower probability of being diagnosed at advanced stage compared with their 
counterparts from the highest quartile counties (77.45, 95%CI: 73.98% – 80.92%). However, 
while not statistically significant, NHW and Hispanic patients from counties with lower 
employment rate had higher prevalence of advanced stage diagnosis compared with their 
counterparts in the highest quartile counties. NHW patients from poorer counties were more 
likely to be diagnosed with advanced stage compared with their counterparts from less poorer 
counties. However, this association was not significant in NHB and Hispanic patients. Stage of 
diagnosis did not significantly differ by counties for all three racial/ethnic groups.  
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Table 3  
 
Factors Contributing to Racial/Ethnic Disparities in Advanced Stage Diagnosis and Receipt of Surgery, by Race/Ethnicity a 
 
Study Variables Advanced Stage Diagnosis 
% b (95%CI) 
Receipt of Surgery 
% b (95%CI) 
 Non-Hispanic 
White 
(n=39,726) 
Non-Hispanic 
Black 
(n=4,295) 
Hispanic 
 
(n=6,256) 
Non-Hispanic 
White 
(n=39,726) 
Non-Hispanic 
Black 
(n=4,295) 
Hispanic 
 
(n=6,256) 
Age at diagnosis       
    18-45 56.29ref 
(54.88 – 57.7) 
58.85 ref 
(55.42 – 62.27) 
53.60 ref 
(51.13 – 56.07) 
94.28 ref 
(93.46 – 95.10) 
85.07 ref 
(82.50 – 87.64) 
94.00 ref 
(92.74 – 95.27) 
    46-55 66.58* 
(65.6 – 67.57) 
69.16 
(66.20 – 72.12) 
64.71* 
(62.28 – 67.14) 
90.21* 
(89.46 – 90.97) 
77.50* 
(75.05 – 79.94) 
85.98* 
(84.33 – 87.62) 
    56-65 72.29* 
(71.44 – 73.13) 
75.60* 
(72.99 – 78.21) 
72.04* 
(69.61 – 74.47) 
86.30* 
(85.63 – 86.98) 
71.15* 
(68.88 – 73.43) 
85.01* 
(83.43 – 86.58) 
    66-75 76.03* 
(75.14 – 76.92) 
78.25* 
(75.50 – 81.01) 
75.61* 
(72.96 – 78.26) 
82.89* 
(82.18 – 83.6) 
65.54* 
(63.08 – 67.99) 
80.33* 
(78.54 – 82.13) 
    >=76 79.73* 
(78.85 – 80.61) 
82.84* 
(80.02 – 85.67) 
77.40* 
(74.28 – 80.52) 
73.40* 
(72.56 – 74.240) 
56.35* 
(53.31 – 59.39) 
69.00* 
(66.31 – 71.70) 
Marital status       
    Not married 72 .00 ref 
(71.37 – 72.63) 
73.42 ref 
(71.91 – 74.94) 
67.06 ref 
(65.41 – 68.71) 
81.36 ref 
(80.84 – 81.87) 
69.35 ref 
(68.07 – 70.62) 
82.97 ref 
(82.01 – 83.93) 
    Married 71.04* 
(70.47 – 71.62) 
71.24 
(68.92 – 73.56) 
65.84 
(64.16 – 67.52) 
84.74* 
(84.26 – 85.22) 
73.95* 
(72.03 – 75.88) 
84.93* 
(83.89 – 85.97) 
Stage       
    Non-advanced - - - 94.12 ref 
(93.56 – 94.68) 
89.11 ref 
(87.14 – 91.08) 
96.44 ref 
(95.45 – 97.44) 
    Advanced - - - 80.14* 
(79.64 – 80.65) 
65.12* 
(63.76 – 66.49) 
79.43* 
(78.42 – 80.43) 
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Study Variables Advanced Stage Diagnosis 
% b (95%CI) 
Receipt of Surgery 
% b (95%CI) 
 Non-Hispanic 
White 
(n=39,726) 
Non-Hispanic 
Black 
(n=4,295) 
Hispanic 
 
(n=6,256) 
Non-Hispanic 
White 
(n=39,726) 
Non-Hispanic 
Black 
(n=4,295) 
Hispanic 
 
(n=6,256) 
       
       
       
Grade        
    Well differentiated 45.97 ref 
(43.87 – 48.06) 
42.15 ref 
(35.52 – 48.78) 
39.43 ref 
(34.72 – 44.14) 
90.86 ref 
(88.94 – 92.78) 
93.05 ref 
(87.16 – 98.95) 
94.88 ref 
(91.07 – 98.70) 
    Moderately   
differentiated 
62.05* 
(60.77 – 63.32) 
64.22* 
(59.94 – 68.50) 
60.21* 
(56.92 – 63.49) 
92.43 
(91.47 – 93.40) 
88.26* 
(84.78 – 91.75) 
93.61 
(91.47 – 95.74) 
    Poorly 
differentiated 
75.79* 
(75.06 – 76.52) 
76.18* 
(73.77 – 78.60) 
71.66* 
(69.52 – 73.81) 
92.20 
(91.69 – 92.71) 
84.70* 
(82.75 – 86.64) 
92.69 
(91.55 – 93.83) 
    Undifferentiated 74.78* 
(73.58 – 75.98) 
76.93* 
(72.48 – 81.37) 
72.03* 
(68.46 – 75.61) 
94.86* 
(94.17 – 95.56) 
86.11* 
(82.75 – 89.48) 
93.04 
(91.20 – 94.88) 
    Unknown 75.39* 
(74.61 – 76.16) 
76.29* 
(74.31 – 78.28) 
69.12* 
(67.10 – 71.14) 
68.51* 
(67.59 – 69.43) 
54.06 
(51.96 – 56.16) 
71.72* 
(70.09 – 73.35) 
Histology        
    Serous 83.19 ref 
(82.62 – 83.77) 
83.68 ref 
(81.83 – 85.52) 
80.26 ref 
(78.54 – 81.98) 
89.65 ref 
(89.15 – 90.15) 
80.73 ref 
(78.97 – 82.50) 
90.33 ref 
(89.28 – 91.38) 
    Mucinous 51.76 
(49.50 – 54.03) 
60.76* 
(54.88 – 66.65) 
50.79* 
(45.93 – 55.64) 
84.42* 
(82.79 – 86.04) 
72.04* 
(66.71 – 77.37) 
86.24* 
(82.97 – 89.50) 
    Endometrioid 45.38* 
(43.63 – 47.14) 
49.80* 
(43.48 – 56.12) 
45.73* 
(41.50 – 49.96) 
91.85* 
(90.31 – 93.39) 
83.11 
(76.79 – 89.43) 
94.59* 
(91.35 – 97.82) 
    Clear cell 39.53* 
(37.42 – 41.63) 
50.66* 
(41.61 – 59.71) 
39.91* 
(34.39 – 45.43) 
93.60* 
(92.21 – 95.00) 
79.64 
(71.42 – 87.86) 
91.37 
(87.99 – 94.74) 
    Other or 
unspecified 
71.36* 
(70.50 – 72.22) 
70.03* 
(67.91 – 72.16) 
64.08* 
(61.92 – 66.23) 
74.25* 
(73.50 – 75.00) 
61.69* 
(59.87 – 63.52) 
75.52* 
(74.07 – 76.97) 
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Study Variables Advanced Stage Diagnosis 
% b (95%CI) 
Receipt of Surgery 
% b (95%CI) 
 Non-Hispanic 
White 
(n=39,726) 
Non-Hispanic 
Black 
(n=4,295) 
Hispanic 
 
(n=6,256) 
Non-Hispanic 
White 
(n=39,726) 
Non-Hispanic 
Black 
(n=4,295) 
Hispanic 
 
(n=6,256) 
       
       
Contextual-level 
factors: 
      
Metro/nonmetro 
residence c 
      
    Metro 71.50 ref 
(71.03 – 71.97) 
73.09 ref 
(71.77 – 74.42) 
66.49 ref 
(65.20 – 67.77) 
82.98 ref 
(82.53 – 83.43) 
70.87 ref 
(69.75 – 71.98) 
83.90 ref 
(83.20 – 84.61) 
    Nonmetro 71.26 
(70.07 – 72.45) 
68.96 
(63.99 – 73.93) 
65.58 
(59.53 – 71.64) 
83.08 
(82.25 – 83.91) 
69.18 
(65.34 – 73.02) 
82.17 
(78.22 – 86.11) 
County education d       
    Highest 72.18 ref 
(71.31 – 73.05) 
71.47 ref 
(67.71 – 75.22) 
66.94 ref 
(62.14 – 71.74) 
83.00 ref 
(82.26 – 83.75) 
69.41 ref 
(66.29 – 72.54) 
84.46 ref 
(81.25 – 87.67) 
    Upper-middle 71.2 
(70.35 – 72.05) 
71.74 
(69.48 – 73.99) 
64.74 
(61.26 – 68.22) 
83.24 
(82.54 – 83.95) 
72.10 
(70.27 – 73.93) 
83.30 
(81.12 – 85.47) 
    Lower-middle 71.32 
(70.33 – 72.32) 
74.80 
(72.26 – 77.34) 
67.20 
(64.41 – 69.99) 
82.88 
(82.08 – 83.68) 
71.03 
(68.89 – 73.17) 
83.23 
(81.68 – 84.79) 
    Lowest 70.91 
(69.78 – 72.04) 
73.01 
(69.87 – 76.15) 
66.39 
(64.29 – 68.49) 
82.78 
(81.81 – 83.76) 
68.83 
(66.18 – 71.47) 
84.24 
(83.06 – 85.42) 
County employment e       
    Highest 70.82 ref 
(69.96 – 71.69) 
77.45 ref 
(73.98 – 80.92) 
64.94 ref 
(60.83 – 69.04) 
83.10 ref 
(82.41 – 83.80) 
71.38 ref 
(68.25 – 74.50) 
85.86 ref 
(83.43 – 88.29) 
    Upper-middle 71.76 
(70.88 – 72.64) 
73.52 
(70.29 – 76.75) 
67.91 
(64.71 – 71.10) 
83.17 
(82.48 – 83.87) 
70.71 
(67.98 – 73.45) 
84.68 
(82.67 – 86.69) 
    Lower-middle 71.91 
(71.04 – 72.79) 
72.19* 
(69.63 – 74.75) 
66.48 
(64.48 – 68.48) 
82.76 
(82.00 – 83.52) 
73.39 
(71.37 – 75.41) 
83.79 
(82.59 – 85.00) 
    Lowest 71.49 
(70.38 – 72.60) 
70.93* 
(68.41 – 73.45) 
65.88 
(63.02 – 68.75) 
82.93 
(82.06 – 83.80) 
68.19 
(66.09 – 70.29) 
82.41* 
(80.81 – 84.00) 
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Study Variables Advanced Stage Diagnosis 
% b (95%CI) 
Receipt of Surgery 
% b (95%CI) 
 Non-Hispanic 
White 
(n=39,726) 
Non-Hispanic 
Black 
(n=4,295) 
Hispanic 
 
(n=6,256) 
Non-Hispanic 
White 
(n=39,726) 
Non-Hispanic 
Black 
(n=4,295) 
Hispanic 
 
(n=6,256) 
       
       
County poverty f       
    Highest 70.44 ref 
(69.43 – 71.45) 
70.80 ref 
(66.44 – 75.16) 
63.49 ref 
(59.07 – 67.91) 
83.70 ref 
(82.84 – 84.56) 
70.31 ref 
(66.77 – 73.85) 
84.15 ref 
(81.50 – 86.81) 
    Upper-middle 71.23 
(70.32 – 72.14) 
71.45 
(67.92 – 74.98) 
63.65 
(59.9 – 67.41) 
82.94 
(82.18 – 83.71) 
68.59 
(65.63 – 71.55) 
84.38 
(82.17 – 86.60) 
    Lower-middle 72.04* 
(71.13 – 72.95) 
72.25 
(69.94 – 74.55) 
66.94 
(64.78 – 69.11) 
83.02 
(82.29 – 83.75) 
70.75 
(68.85 – 72.64) 
83.27 
(82.03 – 84.50) 
    Lowest 72.53* 
(71.40 – 73.66) 
74.48 
(72.20 – 76.77) 
69.00 
(66.31 – 71.70) 
82.11* 
(81.22 – 83.00) 
71.81 
(69.87 – 73.75) 
84.14 
(82.55 – 85.73) 
       
Random effect       
County variance 0.0031 
 
<0.0001 0.0248 0.0527* 
 
<0.0001 
 
<0.0001 
 
Notes: a Adjusted for all the variables listed in the table, year of diagnosis and county random effects. b Average adjusted predicted probabilities. c Metro vs. nonmetro 
categories are based on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S. Department of Agriculture. d 
Sorted by percentage of a county population with less than 9th grade education in ascending order, and categorized into quartiles.  e Sorted by percentage of persons 
aged 16 and over who are unemployed in a county in ascending order, and categorized into quartiles. f Sorted by percentage of persons in a county whose incomes 
are below the 100% federal poverty level threshold in ascending order, and categorized into quartiles.  
CI, confidence interval. ref reference group. * p<0.05 
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Receipt of Surgery Treatment 
 Racial/Ethnic Disparities in Receipt of Surgery Treatment 
 Receipt of surgery treatment varied by race/ethnicity. On average, NHW patients had the 
highest probability of receiving surgery treatment (83.40%, 95%CI: 83.04% - 83.76%) followed 
by Hispanic patients (81.96%, 95%CI: 81.16% - 82.76%) and patients in Other racial/ethnic 
groups (81.94%, 95%CI: 80.92% - 82.97%). NHB patients (77.65%, 95%CI: 76.73% - 78.58%) 
had the lowest probability of receiving surgery (p’s<0.05).  
 Factors Associated with Disparities in Receipt of Surgery 
 Age at diagnosis was positively and significantly associated with receipt of surgery, with 
the youngest group (18-45 years old) having the highest surgery rate (93.81, 95%CI: 93.20% - 
94.41%), and the oldest group (older than 76) having the lowest surgery rate (71.86%, 95%: 
71.11% - 72.62%) (p<0.05). Married patients were significantly more likely to receive surgery 
treatment compared with their unmarried counterparts (81.13% vs. 84.31%, p<0.05). If patients 
were diagnosed at advanced stage, the probability for receiving surgery treatment significantly 
decreased by 14.97 percentage points (94.29% vs. 79.32%, p<0.05). Being insured significantly 
increased the probability of receiving surgery treatment by 5.24 percentage points (84.29% vs. 
80.94%, p<0.05) (Appendix A: Table 2.1). No interaction between race/ethnicity and other 
variables was significantly associated with receipt of surgery.  
 Contextual-level factors including metro/nonmetro residence and all the county-level 
SES indicators were not significantly associated with receipt of surgery. However, the 
probability of receiving surgery treatment varied significantly by county (variance: 0.0451, 
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p=0.0004). When comparing model adjusted for individual-level factors only (results not shown) 
with the full model, the county random effect (variance) decreased from 0.0526 to 0.0451. 
 Factors Contributing to Racial/Ethnic Disparities in Receipt of Surgery 
 Results based on the sub analysis regarding receipt of surgery stratified by race/ethnicity 
are reported in Table 3 (Odds Ratios are presented in Appendix G: Table 3.2).  For patients in all 
three racial/ethnic groups, age at diagnosis was negatively associated with the probability of 
receiving surgery treatment. However, when comparing differences in average probability of 
surgery receipt between the youngest group (18-45 years old) and oldest group (older than 76 
years), the probability decreased by 20.22 percentage points (94.28% vs. 73.40%, p<0.05) in 
NHW patients, 28.72 percentage points (85.07% vs. 56.35%, p<0.05) in NHB patients, and 
25.00 percentage points (94.00% vs. 69.00%, p<0.05) in Hispanic patients. Being married was 
positively and significantly associated with higher probability of receiving surgery treatment for 
patients in all three groups (p’s<0.05). Based on sub analysis including insurance status, the 
association between receipt of surgery treatment and insurance status was only found to be 
significant among NHW and Hispanic patients, but not among NHB patients (Appendix B: Table 
3.1).  Receipt of surgery was also significantly associated with stage at diagnosis for patients in 
all three groups. When diagnosed at advanced (vs. early) stage, the probability of receiving 
surgery treatment decreased by 13.98 percentage points (94.12% vs. 80.14%, p<0.05) for NHW 
patients, 29.33 percentage points (89.11% vs. 65.12%, p<0.05) for NHB patients, and 17.01 
percentage points (96.44% vs. 79.43%, p<0.05) for Hispanic patients.  
 For patients in all racial/ethnic groups, receipt of surgery was not significantly associated 
with metro/nonmetro residence and county-level education. For Hispanic patients, those living in 
counties in the lowest quartile rank of county employment rate were significantly less likely to 
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receive surgery treatment compared to their counterparts in counties in the highest quartile rank 
of county employment rate (82.41% vs. 85.86%, p<0.05). However, the association between 
county-level employment rate and receipt of surgery was not significant for NHB and Hispanic 
patients. County-level poverty was significantly associated with receipt of surgery for NHW 
patients, and patients from the counties in the lowest quartile had significantly lower probability 
of receiving surgery compared with their counterparts from counties in the highest quartile 
(82.11% vs. 83.70%, p<0.05). However, this association was also not found to be significant in 
other two racial/ethnic groups. The average predicted probabilities of receiving surgery 
significantly varied across counties for NHW patients (variance: 0.0527, p<0.0001), but not for 
NHB and Hispanic patients.  
Ovarian Cancer-Cause Specific Mortality 
 Racial/Ethnic Disparities in Ovarian Cancer-Cause Specific Mortality 
 Results based on Cox proportional hazards model with shared frailty are shown in Table 
4. The 5-year ovarian cancer-cause specific mortality varied significantly by counties (variance: 
0.0042, p=0.0010). When comparing model adjusted for individual-level factors only (results not 
shown) with the full model, county random effect (variance) decreased from 0.0055 to 0.0042. 
However, since the county variance was so small and not clinically meaningful, the reported 
Hazard Ratio was not adjusted for random effects. Adjusting for all the variables listed in Table 
1 and year of diagnosis, NHB patients had a 1.24-fold increased hazards of ovarian cancer cause-
specific death compared to NHW patients (95% CI: 1.18 – 1.30, p<0.05). While not statistically 
significant, Hispanic patients and patients in Other racial/ethnic groups had 2% (95%CI: 0.94 – 
1.03) and 4% (95%CI: 0.90 – 1.02) decreased hazards than NHW patients, respectively.  
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Table 4  
Adjusted Hazard Ratios for Ovarian Cancer-Cause Specific Mortality a 
Study Variables Ovarian Cancer-Cause Specific 
Mortality 
(N=54,580) 
HR (95%CI) 
Race/ethnicity  
    Non-Hispanic White Ref 
    Non-Hispanic Black 1.24 (1.18 – 1.30)* 
    Hispanic 0.98 (0.94 – 1.03) 
    Other 0.96 (0.90 – 1.02) 
Age at diagnosis  
    18-45 Ref 
    46-55 1.33 (1.25 – 1.41)* 
    56-65 1.51 (1.43 – 1.60)* 
    66-75 1.84 (1.74 – 1.95)* 
    >=76 2.57 (2.42 – 2.73)* 
Marital status  
    Not married Ref 
    Married 0.86 (0.83 – 0.88)* 
Stage  
    Non-advanced Ref 
    Advanced 4.66 (4.43 – 4.91)* 
Surgery  
    No  Ref 
    Yes 0.32 (0.31 – 0.33)* 
Grade   
    Well differentiated Ref 
    Moderately differentiated 1.91 (1.72 – 2.13) 
    Poorly differentiated 2.33 (2.10 – 2.58) 
    Undifferentiated 2.32 (2.09 – 2.59) 
    Unknown 2.15 (1.94 – 2.39) 
Histology   
    Serous Ref 
    Mucinous 1.63 (1.52 – 1.75)* 
    Endometrioid 0.76 (0.70 – 0.81)* 
    Clear cell 1.31 (1.21 – 1.41)* 
    Other or unspecified 1.23 (1.19 – 1.27)* 
  
Contextual-level factors:  
Metro/nonmetro residence b  
    Metro Ref 
    Nonmetro 1.09 (1.04 – 1.14)* 
County education c  
    Highest Ref 
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Study Variables Ovarian Cancer-Cause Specific 
Mortality 
(N=54,580) 
HR (95%CI) 
    Upper-middle 0.99 (0.94 – 1.04) 
    Lower-middle 0.98 (0.93 – 1.03) 
    Lowest 1.01 (0.95 – 1.08) 
County employment d   
    Highest Ref 
    Upper-middle 0.93 (0.89 – 0.97)* 
    Lower-middle 0.94 (0.89 – 0.99)* 
    Lowest 0.96 (0.90 – 1.01)  
County poverty e  
    Highest Ref 
    Upper-middle 1.06 (1.00 – 1.11)* 
    Lower-middle 1.07 (1.01 – 1.14)* 
    Lowest 1.09 (1.02 – 1.16)* 
  
Random effect  
County variance 0.0042* 
 
Notes: a Adjusted for all the variables listed in the table, year of diagnosis and county random effects. b Metro vs. 
nonmetro categories are based on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic 
Research Service, U.S. Department of Agriculture. c Sorted by percentage of a county population with less than 9th 
grade education in ascending order, and categorized into quartiles.  d Sorted by percentage of persons aged 16 and 
over who are unemployed in a county in ascending order, and categorized into quartiles. e Sorted by percentage of 
persons in a county whose incomes are below the 100% federal poverty level threshold in ascending order, and 
categorized into quartiles.  
HR, hazard ratio. CI, confidence interval.  ref reference group. * p<0.05 
 
 
 Factors Associated with Disparities in Ovarian Cancer-Specific Mortality 
 The risk of death due to ovarian cancer within five years of diagnosis significantly 
increased with age at diagnosis. Patients who were diagnosed after the age of 76 years had a 
2.57-fold increased hazards of death than patients diagnosed at 18-45 years old (95%CI: 2.42 – 
2.73, p<0.05). Being married was a significant protective factor against ovarian cancer death: 
married patients were 14% less likely to die from ovarian cancer compared with unmarried 
patients (HR: 0.86, 95%CI: 0.83- 0.88, p<0.05). Being diagnosed with advanced stage 
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significantly increased the hazards of ovarian cancer death by 4.66-fold (95%CI: .4.43 – 4.91, 
p<0.05). If surgery treatment had been received, the risk of death due to ovarian cancer 
decreased by 68% (HR: 0.32, 95%CI: 0.31 – 0.33, p<0.05). No interaction other than interaction 
between race/ethnicity and insurance was significantly associated with ovarian cancer-cause 
specific mortality (Appendix C: Table 4.1).  
 With respect to contextual-level factors, patients living in nonmetro counties had higher 
risk of death due to ovarian cancer compared with their counterparts living in metro counties 
(HR: 1.09, 95%CI: 1.04 – 1.14, p<0.05). Ovarian cancer cause-specific mortality did not differ 
by county-level education. Regarding county-level employment rate, patients from counties in 
upper-middle (HR: 0.93, 95%CI: 0.89 – 0.97, p<0.05) and lower-middle (0.94, 95%CI: 0.89 – 
0.99, p<0.05) quartiles were less likely to die from ovarian cancer compared with patients from 
counties in the highest quartile; however, the risk of death did not significantly differ between 
the lowest quartile (HR: 0.96, 95%CI: 0.90 – 1.01) and the highest quartile. Ovarian cancer 
cause-specific mortality also significantly varied by county-level poverty, and patients living in 
counties in lower rank had increased risk of death compared with their counterparts living in 
counties in higher rank (p <0.05).  
Factors Contributing to Racial/Ethnic Disparities in Ovarian Cancer- Specific Mortality 
 As shown in Table 5, for patients in all three racial/ethnic groups, the hazards of dying 
from ovarian cancer was positively associated with increasing age. However, when comparing 
the hazards of death between patients diagnosed at age older than 76 and patients diagnosed 
between 18-45 years old, the hazards of ovarian cancer cause-specific death increased by 2.56-
fold for NHW patients (95%CI: 2.38 – 2.76, p<0.05), 2.40-fold for NHB patients (95%CI: 2.01 – 
2.86, p<0.05), and 2.91- fold for Hispanic patients (95%CI: 2.47 – 3.43, p<0.05). The protective 
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effect of being married was only significant in NHW patients (HR: 0.84, 95%CI: 0.82 – 0.87, 
p<0.05) and NHB patients (HR: 0.82, 95%CI: 0.74 – 0.91, p<0.05) but not in Hispanic patients 
(HR: 0.98, 95%CI: 0.90 – 1.07). The effect of insurance status on ovarian cancer mortality also 
varied by race/ethnicity. Being insured significantly decreased the risk of death due to ovarian 
cancer for NHW patients (HR: 0.79, 95%CI: 0.68 – 0.93, p<0.05). However, although not 
significant, being insured was found to be associated with increased risk of ovarian cancer death 
for NHB patients (HR: 1.36, 95%CI: 0.99 – 1.88, p>0.05) and for Hispanic patients (HR: 1.03, 
95%CI: 0.80 – 1.34) (Appendix D: Table 5.1). Being diagnosed at advanced stage was a 
significant risk factor for ovarian cancer cause-specific death for patients in all three racial/ethnic 
groups. However, when diagnosed at advanced (vs. early) stage, the hazards of death due to 
ovarian cancer significantly increased by 4.65- fold in NHW patients (95%CI: 4.38 – 4.95, 
p<0.05), 3.78-fold in NHB patients (95%CI: 3.24 – 4.41, p<0.05), and 5.98 in Hispanic patients 
(95%CI: 5.05 – 7.09, p<0.05). Receipt of surgery significantly decreased risk of ovarian cancer 
death for patients in all three racial/ethnic groups, and the effect sizes were similar across the 
racial/ethnic groups.  
 In regard to contextual-level factors, survival difference by metro/nonmetro residence 
was significant for NHW patients (HR: 1.09 95%CI: 1.04 – 1.15, p<0.05), but not for NHB and 
Hispanic patients. County-level education was not significantly associated with ovarian cancer-
cause specific mortality for patients in either of the three groups. County-level employment rate 
was significantly associated with ovarian cancer-cause specific mortality in NHW patients, and 
patients from counties in the upper-middle (HR: 0.93, 95%CI: 0.88 – 0.97, p<0.05), lower-
middle (HR: 0.93, 95%CI: 0.88 – 0.98, p<0.05) and lowest quartile (HR: 0.93, 95%CI: 0.87 – 
0.99, p<0.05) had significantly higher mortality compared with patients from the highest quartile 
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counties, respectively. However, these associations were not significant for patients from other 
racial/ethnic groups. Similarly, the association between county-level poverty and ovarian cancer-
cause specific mortality was significant only in NHW patients, and patients from lower quartile 
counties had higher risk of ovarian cancer death than patients from the highest quartile counties 
(p’s<0.05). Ovarian cancer-cause specific mortality significantly varied by county, but only for 
NHW patients (variance: 0.0044, p=0.0010).  
 
 
Table 5  
Factors Contributing to Disparities in Ovarian Cancer-Cause Specific Mortality, by 
Race/Ethnicity a 
Study Variables Ovarian Cancer-Cause Specific Mortality 
HR (95%CI) 
 Non–Hispanic White 
(n=39,726) 
Non–Hispanic Black 
(n=4,295) 
Hispanic 
(n=6,256) 
Age at diagnosis    
    18-45 Ref. Ref. Ref. 
    46-55 1.29 (1.19 – 1.39)* 1.58 (1.33 – 1.88)* 1.36 (1.17 – 1.59)* 
    56-65 1.51 (1.40 – 1.62)* 1.61 (1.36 – 1.91)* 1.61 (1.38 – 1.87)* 
    66-75 1.82 (1.69 – 1.96)* 1.90 (1.60 – 2.25)* 2.01 (1.72 – 2.34)* 
    >=76 2.56 (2.38 – 2.76)* 2.40 (2.01 – 2.86)* 2.91 (2.47 – 3.43)* 
Marital status    
    Not married Ref. Ref. Ref. 
    Married 0.84 (0.82 – 0.87)* 0.82 (0.74 – 0.91)* 0.98 (0.90 – 1.07) 
Stage    
    Non-advanced Ref. Ref. Ref. 
    Advanced 4.65 (4.38 – 4.95)* 3.78 (3.24 – 4.41)* 5.98 (5.05 – 7.09)* 
Surgery    
    No  Ref. Ref. Ref. 
    Yes 0.32 (0.31 – 0.34)* 0.33 (0.30 – 0.38)* 0.30 (0.27 – 0.35)* 
Grade     
    Well differentiated Ref. Ref. Ref. 
    Moderately   
differentiated 
1.84 (1.63 – 2.08)* 2.48 (1.68 – 3.67)* 1.87 (1.35 – 2.59)* 
    Poorly differentiated 2.22 (1.97 – 2.49)* 2.79 (1.92 – 4.07)* 2.37 (1.74 – 3.24)* 
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Study Variables Ovarian Cancer-Cause Specific Mortality 
HR (95%CI) 
 Non–Hispanic White 
(n=39,726) 
Non–Hispanic Black 
(n=4,295) 
Hispanic 
(n=6,256) 
    Undifferentiated 2.21 (1.95 – 2.50)* 2.98 (2.00 – 4.44)* 2.27 (1.63 – 3.16)* 
    Unknown 2.10 (1.87 – 2.37)* 2.59 (1.78 – 3.78)* 1.85 (1.35 – 2.53)* 
Histology     
    Serous Ref. Ref. Ref. 
    Mucinous 1.51 (1.39 – 1.65)* 2.30 (1.89 – 2.81)* 2.07 (1.70 – 2.52)* 
    Endometrioid 0.72 (0.66 – 0.78)* 0.86 (0.67 – 1.09) 0.97 (0.79 – 1.20) 
    Clear cell 1.26 (1.15 – 1.38)* 1.70 (1.25 – 2.30)* 1.77 (1.39 – 2.25)* 
    Other or unspecified 1.19 (1.15 – 1.24)* 1.31 (1.17 – 1.46)* 1.41 (1.27 – 1.57)* 
    
Contextual-level factors:    
Metro/nonmetro  
residence b 
   
    Metro Ref. Ref. Ref. 
    Nonmetro 1.09 (1.04 – 1.15)* 1.05 (0.89 – 1.25) 1.20 (0.97 – 1.5) 
County education c    
    Highest Ref. Ref. Ref. 
    Upper-middle 0.98 (0.93 – 1.04) 0.98 (0.83 – 1.15) 1.02 (0.82 – 1.26) 
    Lower-middle 0.97 (0.92 – 1.03) 0.99 (0.83 – 1.17) 1.05 (0.86 – 1.28) 
    Lowest 0.99 (0.93 – 1.06) 1.03 (0.85 – 1.24) 1.10 (0.88 – 1.37) 
County employment d     
    Highest Ref. Ref. Ref. 
    Upper-middle 0.93 (0.88 – 0.97)* 0.93 (0.78 – 1.11) 0.92 (0.78 – 1.09) 
    Lower-middle 0.93 (0.88 – 0.98)* 1.12 (0.95 – 1.31) 0.86 (0.71 – 1.04) 
    Lowest 0.93 (0.87 – 0.99)* 1.13 (0.95 – 1.35) 0.84 (0.69 – 1.02) 
County poverty e    
    Highest Ref. Ref. Ref. 
    Upper-middle 1.06 (1.00 – 1.12) 1.05 (0.87 – 1.26) 1.07 (0.90 – 1.28) 
    Lower-middle 1.09 (1.02 – 1.16)* 0.99 (0.82 – 1.19) 1.07 (0.88 – 1.30) 
    Lowest 1.14 (1.06 – 1.23)* 0.92 (0.76 – 1.12) 1.16 (0.94 – 1.44) 
    
Random effect    
County variance 0.0044* 
 
0.0032 
 
<0.0001 
 
Notes: a Adjusted for all the variables listed in the table, year of diagnosis and county random effects. b Metro vs. 
nonmetro categories are based on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic 
Research Service, U.S. Department of Agriculture. c Sorted by percentage of a county population with less than 9th 
grade education in ascending order, and categorized into quartiles.  d Sorted by percentage of persons aged 16 and 
over who are unemployed in a county in ascending order, and categorized into quartiles. e Sorted by percentage of 
persons in a county whose incomes are below the 100% federal poverty level threshold in ascending order, and 
categorized into quartiles.  
HR, hazard ratio. CI, confidence interval.  Ref., reference group. * p<0.05 
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Changes in Racial Disparities over Time 
 Results of Joinpoint regression analysis which tested the change in racial/ethnic 
disparities in ovarian cancer diagnosis, surgery treatment and survival over time are presented in 
Figures 1-3. Adjusting for variables listed in Table 1, except for insurance status, racial/ethnic 
disparities in advanced stage diagnosis, receipt of surgery and ovarian cancer-cause specific 
mortality did not vary significantly from 2001 to 2012 (all p’s >0.05).  
 
 
 
 
 
Figure 1. Racial/Ethnic Disparities in Advanced Stage Diagnosis: Trend over Years 2001-2012 
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Figure 2. Racial/Ethnic Disparities in Receipt of Surgery: Trend over Years 2001-2012 
 
 
Figure 3. Racial/Ethnic Disparities in Ovarian Cancer-Cause Specific Mortality: Trend over 
Years 2001-2012 
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CHAPTER 5 
DISCUSSION 
 This study examined racial/ethnic disparities in ovarian cancer advanced stage diagnosis, 
receipt of surgery treatment, and survival outcome, and assessed trend in racial/ethnic disparities 
over 12 years using longitudinal panel dataset. Several individual- and contextual-level factors 
which contribute to those racial/ethnic disparities were identified. Based on most recent national 
cancer registry data, this study updates the knowledge base on changes in ovarian cancer 
racial/ethnic disparities over time.  
 Racial/ethnic disparities in ovarian cancer diagnosis, treatment, and survival may be 
attributed to multiple factors, such as tumor biology, genetic differences, healthcare accessibility 
and quality, or a combination of those factors. This study focused on assessing effects of 
individual- and contextual-level socio demographic and economic characteristics on ovarian 
cancer racial/ethnic disparities, while adjusting for tumor pathological differences.  
 
Racial/Ethnic Disparities 
 Compared to NHB patients, NHB patients have a significant disadvantage in ovarian 
cancer, specifically in advanced stage diagnosis, receipt of surgery treatment, and ovarian cause-
specific mortality. This finding is consistent with many previous studies based on national- or state- 
level data (Chan, et al., 2008; Howell, et al., 2013; Morris, Sands, & Smith, 2010; Terplan, et al., 
2012). Two studies had either contrary or insignificant findings regarding stage of diagnosis 
between the two racial groups; however, the results were based on unadjusted analysis (Du, et al., 
2008; Kim, et al., 2010). In the current study on NHB patients living in counties with the 
employment rate ranked in the first quartile were less likely to be diagnosed at advanced stage. 
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This finding suggests that certain contextual-level characteristics, such as county-level 
employment rate or other related factors, may be contributing to racial/ethnic disparities in ovarian 
cancer diagnosis. 
 The study suggests no significant differences in stage of diagnosis and survival between 
Hispanic and NHW patients. However, Hispanic patients have a significantly lower probability of 
receiving surgery treatment compared with NHW patients. Definitive conclusions regarding 
ovarian cancer racial/ethnic disparities between Hispanic and Other racial/ethnic groups have not 
been established in previous studies, primarily due to the limited data on ovarian cancer cases 
among Hispanic women. One study based on 1996-2006 California Cancer Registry data found no 
significant differences on stage of diagnosis between Hispanics and NHW. This finding is 
consistent with my finding (Morris, et al., 2010). The current study also indicates that Hispanic 
patients have the youngest mean age at diagnosis (55.63 years), followed by patients from Other 
racial/ethnic groups (55.88 years), and NHBs (59.57 years). NHWs have the oldest mean age at 
diagnosis (62.55 years). Based on 2000-2004 SEER 12 data, which included 1,215 Hispanic 
ovarian cancer patients, Ibeanu and Diaz-Montes’s study (2005) also supports my result by 
indicating that Hispanic are significantly more likely to be diagnosed at a younger age compared 
to NHWs and NHBs. Findings of Ibeanu and Diaz-Montes that Hispanics patients were 
significantly less likely to be diagnosed with ovarian cancer at advanced stage compared to NHW 
patients was based on unadjusted analysis (Ibeanu and Diaz-Montes, 2005). Adjustment for 
individual socio demographic characteristics, tumor pathological characteristics, metro/nonmetro 
residence and county SES, the current study does not find a significant difference in ovarian cancer 
advanced stage diagnosis between Hispanics and NHWs.  
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Individual-Level Factors Contributing to Racial/Ethnic Disparities 
 Age 
 Being diagnosed at a younger age has long been associated with better health outcomes for 
cancer patients. In the current study, younger age at diagnosis was found to be independently 
associated with decreased risk of advanced stage diagnosis, increased probability of receiving 
surgery treatment, and decreased hazards due to ovarian cancer. This age advantage remained in 
all racial/ethnic subpopulations. However, to what extend age at diagnosis can affect each level of 
the ovarian cancer continuum differs by race/ethnicity. For example, based on the stratified (by 
race/ethnicity) and adjusted results, when comparing the probabilities of receiving surgery 
treatment between women diagnosed at the age of 76 or older and those who were diagnosed 
between 18-45 years, the differences in surgery rates between these two age groups are 20.00, 
28.72 and 25.00 percentage points for NHW, NHB, and Hispanic patients, respectively. This result 
indicates age at diagnosis has a stronger association with receipt of surgery for NHB patients and 
Hispanic patients than NHW patients. In other words, compared to NHW patients, NHB and 
Hispanic patients may be more likely to forgo surgery treatment due to age consideration. Similarly, 
differences in age at diagnosis may also contribute differently to ovarian cancer cause-specific 
death by racial/ethnic groups. Based on the results of Cox proportional hazard models stratified by 
race/ethnicity, when comparing women diagnosed at age of 76 or older to those who were 
diagnosed between the ages of 18-45, the ovarian cancer-cause specific hazard ratios were 2.56, 
2.40, and 2.91 for NHWs, NHBs, and Hispanics, respectively, which indicates that being 
diagnosed at an older age may be a stronger risk factor for ovarian cancer-cause specific death for 
Hispanic patients compared to their NHW and NHB counterparts.  
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Marital Status 
 Similar to age, in this study, marital status was also found to be a significant factor for 
ovarian cancer early stage of diagnosis, receipt of surgery, and survival. This finding is consistent 
with and supported by a study based on 2004-2008 SEER data, which revealed the advantages of 
being married in cancer diagnosis, treatment, and survival for patients of the top 10 lethal cancers 
(Aizer, et al., 2013). One study has emphasized the survival advantage for married ovarian cancer 
patients and indicated that advantage might be attributed to psychosocial support potentially 
altering immune function (Mahdi, et al., 2013). Another possible explanation regarding the 
marriage protective effect on general health is related to greater economic resources (Trovato & 
Lauris, 1989), which might be related to increased healthcare accessibility and higher quality of 
life. The current study finds significant association between being married and decreased 
probability of advance stage diagnosis, as well as increased probability of receiving surgery 
treatment. However, because I could not control for individual-level social economic status, 
whether this marriage advantage can be contributed to higher SES needs further examination.   
 A study based on the Health Retirement Survey data suggested about variation of 
association between marital status and general health by race and ethnicity. Adjusted for SES and 
baseline health status, compared to NHW women, for NHBs being married is significantly more 
protective against the 2-year mortality (Beckett & Elliott, 2002). In the current study, as specific 
to each level of the ovarian cancer continuum, variation in significance of association between 
marital status and ovarian cancer diagnosis and survival is observed across racial/ethnic groups. 
Being married is a significant protective factor for advanced stage diagnosis only for NHW patients, 
but not for NHB and Hispanic groups. The protective effect on survival is only significant for 
NHW and NHB patients, but not for the Hispanic patients. Similarly, whether this variation can be 
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explained by individual- SES or difference in healthcare accessibility and quality still needs further 
examination. Furthermore, because the sample sizes for NHB and Hispanics are relatively much 
smaller compared with NHWs, the study findings need to be replicated on samples with larger 
representation of NHB and Hispanic patients.  
 Insurance Status 
 Due to limited information on health insurance status, all the analysis with insurance status 
were conducted using sub models with cases diagnosed in 2007 and later. Based on the primary 
model which combined all racial/ethnic groups, being insured is significantly associated with 
increased probability of receiving surgery, but when stratified by race/ethnicity, this association is 
only significant among NHW and Hispanic patients (but not in NHB patients). However, being 
covered by health insurance does not mean that the ovarian cancer surgery treatment procedures 
are covered by insurance plan; the proportion of cost being covered may vary based on the 
insurance types. For example, it has been reported that compared to NHWs, NHBs were more 
likely to be publicly insured and less likely to have commercial insurance (Bristow, et al., 2011). 
However, due to the small proportion of uninsured cases and lack of information on types of 
insurance plan, this conclusion needs to be further confirmed in samples with higher proportion of 
uninsured cases and with more specific information on insurance types. No significant association 
between insurance status and the probability of advanced stage diagnosis is observed in either the 
primary model or stratified models. I was not surprised to find the absence of significant 
association between insurance status and advanced stage diagnosis, since ovarian cancer screening 
tests were not generally recommended and applied to general population due to limited tests 
specificity and potential harms, as a result, being health insured may not be a powerful factor to 
promote effective ovarian cancer screening. Regarding insurance effect on survival outcome, the 
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results from this study indicate interaction effect of race/ethnicity and insurance status. When 
stratified by race/ethnicity, being insured was found to be a significant protective factor against 
ovarian cancer-cause specific death for NHW patients, but significant risk factor for NHB patients; 
and has no significant effect on survival for Hispanic patients. Similarly, one possible explanation 
could still be the difference in type of insurance plan. For example, one study based on clinical 
record suggested public insurance was associated with increased hazard of ovarian cancer 
mortality (Mishka Terplan, et al., 2008).  
 Advanced Stage Diagnosis and Receipt of Surgery 
 Additionally, models examining ovarian cancer-cause specific mortality were adjusted for 
advanced stage diagnosis and receipt of surgery. The results based on the primary model (with all 
racial/ethnic groups) are consistent with previous studies; there is a significant risk effect for being 
diagnosed at advanced stage, and a significant protective effect for receiving surgery treatment on 
survival outcome. The beneficial effect on ovarian cancer survival from receiving surgery 
treatment remained in stratified models, and the effect sizes were similar across racial/ethnic 
groups. However, the association between advanced stage diagnosis and ovarian cancer survival 
does varies across racial/ethnic groups. Based on the stratified models, adjusting for receipt of 
surgery and other covariates, being diagnosed at advanced stage significantly increased ovarian 
cancer death by 4.65-folds for NHW patients, 3.78-folds in NHB patients, and 5.98-folds in 
Hispanic patients. Other potentially influencing factors such as genetic, biological, comorbidity 
and other related factors are required to better explain variation in association between stage at 
diagnosis and survival by race/ethnicity.  
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Contextual-level Factors Contributing to Racial/ethnic Disparities 
 Metro/Nonmetro Residence 
 In this study, the metro/nonmetro residence was treated as a contextual-level factor, and a 
study on metro/nonmetro differences was conceptually a rural/urban (the term which was used in 
most other related studies) difference. This study used the terms metro/nonmetro to be consistent 
with the RUCC classification system. Based on the adjusted results, metro/nonmetro residence is 
not significantly associated with advanced stage diagnosis and receipt of surgery treatment in 
either the primary model or any of the race/ethnicity stratified models. Living in nonmetro counties 
is a significant protective factor against ovarian cancer specific death based on the primary model; 
however, when stratified by race/ethnicity, this association is only found in NHW patients, but not 
in other two groups. The finding on the nonmetro survival advantage is contrary to the 
investigator’s initial hypothesis that ovarian cancer patients living in metro counties have lower 
ovarian cancer mortality. This hypothesis was based on the fact that generally, people living in 
metro areas tend to have better healthcare accessibility and quality. Based on the investigator’s 
literature review, very few studies have reported on ovarian cancer disparities by rural/urban 
residence, especially based on the U.S. population. Only one study based on the SEER-Medicare 
linked database suggested ovarian cancer patients in rural areas were more likely to have surgery 
at a low-volume hospital than residents of urban communities. However, according to this study, 
hospital surgery volume was not significantly associated with ovarian cancer outcome (Schrag et 
al., 2006). Yet, in a study conducted in Poland, living in urban areas was associated with being 
exposed to increased ovarian cancer risk factors, such as lower parity, higher education level and 
experiencing menarche at an earlier age (Szpurek, et al., 2013).  Because the sample of the current 
study consisted of a very small proportion of nonmetro residents (11.11%), and this proportion 
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was even smaller among NHB (9.39%) and Hispanic (3.96%) patients, it is possible that the study 
sample size for NHB and Hispanic patients may be not large enough to generate statistically 
significant results. The small sample for minority patients from nonmetro areas may also indicate 
that although more minority populations are majorly resident in rural area (The Housing Assistance 
Council, 2012), the SEER cancer registry data mainly included minority patients living in urban 
areas. In other words, cases which are diagnosed and treated in urban healthcare facilities are more 
likely to be included into the cancer registry records.    
 County-level SES (Education, Employment and Poverty) 
 In this study, county-level SES was operationalized with three separate variables (rather 
than an index): county-level education, employment, and poverty degree. The study results 
indicate that ovarian cancer advanced stage diagnosis, receipt of surgery, and survival do not vary 
significantly by county-level education.  
 Living in poorer counties is significantly associated with increased probability of advanced 
stage diagnosis. However, this association is only significant in NHWs but not in NHBs and 
Hispanics. Another interesting finding is that the association between county-level employment 
and advanced stage diagnosis varies by race/ethnicity. Living in counties with lower employment 
rate had a significant protective effect against advanced stage diagnosis for NHB patients; however, 
although not statistically significant, lower county employment rate is a risk factor for advanced 
stage diagnosis for NHW and Hispanic patients.  
 Receipt of surgery is not significantly associated with any of the county SES measurements. 
Regarding the ovarian cancer cause-specific mortality, county-level employment and poverty are 
significantly associated with ovarian cancer death for NHW patients but not for NHB and Hispanic 
patients. While living in poorer counties is associated with higher ovarian cancer mortality, living 
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in counties with lower employment is associated with lower risk ovarian cancer death.  
 The association between higher contextual-level SES and better health outcomes has been 
well established by previous studies, as people living in higher contextual-level SES usually have 
better access to healthcare services (CDC, 2014b; Kirby & Kaneda, 2005). On the contrary, several 
studies have also indicated disadvantage of living in higher contextual-level SES community 
(Robert, et al., 2004; Singh, et al., 2012). For instance,  Robert et al found that compared to women 
living in lower SES communities, those living in higher SES communities had greater odds of 
having breast cancer (Robert, et al., 2004). Therefore, explanation of contextual-level SES effect 
on health outcomes should not always focus on unequal access to healthcare services. In the current 
study, the findings on the negative effect of living in counties with higher employment rate may 
be explained by differences in exposure of other ovarian cancer risk factors such as lower parity 
and higher education. 
 
County Variance 
 Results of the multilevel analysis suggest the probability of advanced stage diagnosis does 
not significantly vary by county in either primary model (i.e., adjusting for all racial/ethnic groups) 
or models stratified by race/ethnicity. This study finds a significant but slight county variance in 
surgery receipt and ovarian cancer-cause specific mortality; however, the minor and significant 
county variance is only observed in NHW patients but not in other two racial/ethnic groups. The 
county random effect decreases when contextual-level factors are added to the models, which 
indicates that the variation of ovarian cancer outcomes at county level may be partially explained 
by these contextual-level factors. However, since the ovarian cancer prevalence is relative low 
compared to other major cancer diseases such as breast cancer and cervical cancer, the distribution 
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of reported cases in certain counties might be rare, especially for minority patients which are 
underrepresented in this study sample, therefore, a lack of statistical power due to limited minority 
cases may contribute to the insignificant county variance in NHB and Hispanic subpopulations.  
 
Racial/Ethnic Disparities Change over Time 
 This study does not find a significant change in ovarian cancer racial/ethnic disparities 
from 2001 to 2012. Based on the Joinpoint trend analysis, when comparing the racial/ethnic ORs 
and HRs for each two of the three racial/ethnic groups over time, no significant changes are found 
between any of the two racial/ethnic group combinations. This result indicates that the extend of 
racial/ethnic disparities in ovarian cancer advanced stage diagnosis, receipt of surgery treatment, 
and survival has remained stable from 2001 to 2012 among NHW, NHB, and Hispanic patients. 
To my knowledge, changes in prevalence of ovarian cancer advanced stage diagnosis and receipt 
of surgery over time have not been examined by race/ethnicity. Terplan et al’s study based on 
SEER 9 data assessed racial survival differences between NHW and NHB patients from 1973 to 
2007 (M. Terplan, et al., 2012). During this study period, racial disparities in survival (adjusted for 
registry, tumor stage and marital status) had been widened between the two racial groups due to 
differences in the receipt of surgery. However, since HRs were measured by every five-year 
diagnosis cohort, annual change in HRs, and cases diagnosed in recent years were not actually 
assessed by this study. Although the current study period partially overlaps with the 1973-2007 
study period, the two studies differ in measurement and assessment, thus, by including more recent 
data, the current study yield different results: there is no significant change in racial/ethnic 
disparities from 2001 to 2012. Because the data used in the current study did not contain 
information on chemotherapy and newly emerged treatment such as antiangiogenic therapy, future 
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studies should assess changes in ovarian cancer disparities related to other types of treatment. 
 
Limitations and Strengths 
This study had several limitations. First, it has been shown that the prevalence of BRCA1 
and BRCA2 mutation, which was strongly associated with ovarian cancer development, can vary 
by racial/ethnic groups in the U.S. (John et al., 2007; National Cancer Institute, 2015b).  However, 
family ovarian cancer history and genetic influence were not controlled for in this study due to 
unavailability of such data. Second, because of the incomplete treatment information, it is types of 
treatment other than surgery were not examined in this study. The current three main types of 
treatment for ovarian cancer include surgery, chemotherapy and radiotherapy. Racial disparities 
regarding the receipt of chemotherapy have been reported in previous studies (Du, et al., 2008). 
However, since SEER data do not provide information on the receipt of chemotherapy, assessing 
disparities in receipt of chemotherapy and its contribution to racial/ethnic disparities in ovarian 
cancer outcomes is not possible in this study. Based on the SEER data, only less than 2 percent 
ovarian cancer patients received radio therapy. Due to considerations of statistical power, this study 
did not assess the effect of radiation therapy on ovarian cancer outcomes. Thirdly, individual 
insurance status information was only available for patients diagnosed from the year of 2007 and 
later. As a result, this study was not able to assess the effect of insurance status for cases diagnosed 
earlier; thus, the insurance status was not adjusted in the trend analysis. Finally, an important 
limitation of this study is the limited sample size of minority patients, especially NHB patients 
which accounts for less than 8 percent of the total study population. When stratified by 
race/ethnicity, the assessment of association between certain factors and interested outcomes might 
be insignificant due to limited statistical power.  
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This study also have several strengths. First, it is based on the most updated national level 
cancer registry data which allowed for a large sample size for multivariate and multilevel statistical 
analysis, and the large sample size also increased the representativeness of the study sample. 
Second, the inclusion of multi-year cohorts defined by time of diagnosis enabled the analysis to 
control for and study on time effects on interested outcomes.  
  
Contributions 
 The current study updates the knowledge about racial/ethnic disparities in ovarian cancer 
diagnosis, surgery treatment and survival based on most recent national-level cancer research data. 
Furthermore, by applying a multilevel social ecological research approach, it provides new 
evidence on the effect of contextual-level factors on ovarian cancer outcomes. It also provides new 
insights into mechanisms through which racial/ethnic disparities in ovarian cancer are developed, 
and updates information on the racial/ethnic disparities change over time. Finally, this study also 
initiates several new future research endeavors to address the aforementioned limitations and to 
further explore other potential individual- and contextual-level factors contributing to racial/ethnic 
disparities in ovarian cancer diagnosis, treatment, and survival.  
 
Conclusions and Implication 
 This study confirms that racial/ethnic disparities exist at each level of the ovarian cancer 
continuum diagnosis, treatment, and survival, and the extent of these racial/ethnic disparities has 
remained stable from 2001-2012. Both individual- and contextual-level factors contribute to the 
ovarian cancer racial/ethnic disparities. The effect of these factors can varies by race/ethnicity, and 
should be examined separate.  
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 As certain subpopulations experience excessive health burdens related to ovarian cancer, 
multilevel efforts are needed to improve ovarian cancer diagnosis and treatment. An efficient way 
to identify and target these vulnerable populations can be based on a combination of individual-
level and contextual-level factors associated with ovarian cancer outcomes. Specific policy 
interventions should focus on subpopulations at a greater risk for ovarian cancer diagnosed at a 
later stage, for forgoing surgery treatment (NHB and Hispanic patients); and ovarian cancer 
mortality (e.g. Hispanic patients who were diagnosed at advanced stage). Potential policy 
recommendation may include (1) developing or modifying insurance plans to encourage ovarian 
cancer screening, and to improve reimbursement for potential treatments for populations at risk; 
(2) developing standardized protocols and procedures for ovarian cancer treatment to reduce the 
probability of forgoing treatment due to lack of information or healthcare resources.  Future studies 
should focus on exploring other factors which were not assessed in this study but may potentially 
influence racial/ethnic disparities in ovarian cancer outcomes, such as family history, behavioral 
factors, individual SES, and other types of treatment. 
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APPENDICES 
 
Appendix A: Table 2.1 
Models with Insurance Status: Adjusted Prevalence of Advanced Stage Diagnosis and Receipt of 
Surgery (N=27,539) a 
Study Variables Advanced Stage Diagnosis 
% b (95%CI) 
Receipt of Surgery 
% b (95%CI) 
Race/ethnicity   
    Non-Hispanic White 68.41 (67.79 – 69.03)ref 83.27 (82.78 – 83.77) ref 
    Non-Hispanic Black 71.15 (69.24 – 73.06)* 78.27 (77.05 – 79.49)* 
    Hispanic 69.11 (67.58 – 70.64) 81.41 (80.30 – 82.52)* 
    Other 69.15 (67.39 – 70.91) 82.34 (80.96 – 83.71) 
Age at diagnosis   
    18-45 53.86 (52.32 – 55.41) ref 94.81 (94.01 – 95.60) ref 
    46-55 64.17 (63.00 – 65.34)* 89.21 (88.34 – 90.08)* 
    56-65 70.43 (69.42 – 71.45)* 85.37 (84.56 – 86.18)* 
    66-75 74.36 (73.25 – 75.48)* 80.85 (79.95 – 81.75)* 
    >=76 78.48 (77.32 – 79.65)* 70.31 (69.21 – 71.41)* 
Marital status   
    Not married 69.01 (68.27 – 69.74) ref 80.94 (80.35 – 81.52) ref 
    Married 68.54 (67.85 – 69.24) 84.29 (83.72 – 84.87)* 
Insurance    
    Uninsured 69.24 (66.95 – 71.52) ref 77.42 (75.37 – 79.47) ref 
    Insured 68.74 (68.23 – 69.25) 82.66 (82.20 – 83.12)* 
Stage   
    Non-advanced – 93.62 (92.96 – 94.28) ref 
    Advanced – 79.36 (78.77 – 79.95)* 
Grade    
    Well differentiated 40.87 (38.31 – 43.43) ref 93.80 (91.65 – 95.95) ref 
    Moderately differentiated 57.81 (56.13 – 59.49)* 92.87 (91.59 – 94.14) 
    Poorly differentiated 72.35 (71.42 – 73.29)* 92.12 (91.50 – 92.74) 
    Undifferentiated 72.04 (70.66 – 73.43)* 94.80 (94.03 – 95.58) 
    Unknown 73.59 (72.68 – 74.51)* 67.85 (66.80 – 68.90)* 
Histology    
    Serous 81.40 (80.68 – 82.11) ref 88.06 (87.47 – 88.65) ref 
    Mucinous 47.49 (44.66 – 50.32)* 84.72 (82.67 – 86.77)* 
    Endometrioid 42.65 (40.42 – 44.89)* 92.82 (90.88 – 94.76)* 
    Clear cell 38.64 (36.23 – 41.06)* 93.27 (91.58 – 94.96)* 
    Other or unspecified 67.17 (66.14 – 68.20)* 74.56 (73.73 – 75.40)* 
   
Interaction: race/ethnicity * 
county employment 
  
County employment: highest   
    Non-Hispanic White 67.96 (66.74 – 69.18) ref – 
    Non-Hispanic Black 75.68 (71.47 – 79.88)* – 
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Study Variables Advanced Stage Diagnosis 
% b (95%CI) 
Receipt of Surgery 
% b (95%CI) 
    Hispanic 67.77 (63.74 – 71.80) – 
    Other 70.54 (67.42 – 73.65) – 
County employment: upper-
middle 
  
    Non-Hispanic White 69.14 (67.93 – 70.34) ref – 
    Non-Hispanic Black 68.65 (64.16 – 73.13) – 
    Hispanic 69.46 (66.59 – 72.33) – 
    Other 68.54 (65.25 – 71.83) – 
County employment: lower-
middle 
  
    Non-Hispanic White 68.38 (67.03 – 69.73) ref – 
    Non-Hispanic Black 69.94 (66.70 – 73.18) – 
    Hispanic 67.91 (65.52 – 70.31) – 
    Other 67.74 (64.73 – 70.76) – 
County employment: lowest   
    Non-Hispanic White 68.15 (66.77 – 69.53) ref – 
    Non-Hispanic Black 70.27 (67.43 – 73.10) – 
    Hispanic 71.43 (68.79 – 74.07)* – 
    Other 69.80 (65.26 – 74.34) – 
   
Contextual-level factors:   
Metro/nonmetro residence c   
    Metro 68.84 (68.31 – 69.37) ref 82.52 (82.02 – 83.01) ref 
    Nonmetro 68.11 (66.45 – 69.76) 82.22 (81.10 – 83.33) 
County education d   
    Highest 68.96 (67.83 – 70.08) ref 83.21 (82.35 – 84.08) 
    Upper-middle 68.84 (67.76 – 69.91) 82.57 (81.73 – 83.42) 
    Lower-middle 68.74 (67.70 – 69.77) 82.12 (81.22 – 83.03) 
    Lowest 68.52 (67.27 – 69.77) 82.03 (80.91 – 83.14) 
County employment e    
    Highest 68.80 (67.68 – 69.92) ref 82.59 (81.74 – 83.45) ref 
    Upper-middle 69.09 (68.01 – 70.16) 83.04 (82.15 – 83.92) 
    Lower-middle 68.39 (67.28 – 69.50) 82.59 (81.49 – 83.69) 
    Lowest 68.92 (67.73 – 70.11) 81.78 (80.84 – 82.72) 
County poverty f   
    Highest 67.92 (66.75 – 69.10) ref 82.78 (81.81 – 83.75) ref 
    Upper-middle 68.23 (67.16 – 69.31) 81.96 (81.01 – 82.92) 
    Lower-middle 69.44 (68.34 – 70.54) 82.90 (81.96 – 83.85) 
    Lowest 69.53 (68.20 – 70.87) 82.23 (81.25 – 83.21) 
   
Random effect   
County variance <0.0001 
 
0.0382* 
 
Notes: a Adjusted for all the variables listed in the table, year of diagnosis, interactions between race/ethnicity and 
county employment, and county random effects. b Average adjusted predicted probabilities. c Metro vs. nonmetro 
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categories are based on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research 
Service, U.S. Department of Agriculture. d Sorted by percentage of a county population with less than 9th grade 
education in ascending order, and categorized into quartiles.  e Sorted by percentage of persons aged 16 and over who 
are unemployed in a county in ascending order, and categorized into quartiles. f Sorted by percentage of persons in a 
county whose incomes are below the 100% federal poverty level threshold in ascending order, and categorized into 
quartiles.  
CI, confidence interval.  ref reference group. * p<0.05
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Appendix B: Table 3.1 
 
Models with Insurance Status: Factors Contributing to Disparities in Advanced Stage Diagnosis and Receipt of Surgery, by 
Race/Ethnicity a 
 
Study Variables Advanced Stage Diagnosis 
% b (95%CI) 
Receipt of Surgery 
% b (95%CI) 
 Non–Hispanic 
White 
(n=19.328) 
Non–Hispanic 
Black 
(n=2,278) 
Hispanic 
(n=3.460) 
Non–Hispanic 
White 
(n=19.328) 
Non–Hispanic 
Black 
(n=2,278) 
Hispanic 
(n=3.460) 
Age at diagnosis       
    18-45 54.71 ref  
(52.62 – 56.79) 
56.99 ref  
(51.95 – 62.03) 
51.78 ref  
(48.63 – 54.93) 
95.40 ref  
(94.34 – 96.46) 
87.66 ref  
(84.10 – 91.22) 
94.17 ref 
(92.50 – 95.84) 
    46-55 64.90*  
(63.48 – 66.32) 
67.98* 
(63.74 – 72.21) 
63.74*  
(60.66 – 66.82) 
91.09 * 
(90.09 – 92.10) 
75.69* 
(72.23 – 79.15) 
86.63*  
(84.50 – 88.75) 
    56-65 70.43*  
(69.25 – 71.60) 
76.08*  
(72.62 – 79.54) 
70.21*  
(67.09 – 73.34) 
86.72*  
(85.87 – 87.57) 
71.97*  
(68.97 – 74.97) 
84.54*  
(82.45 – 86.64) 
    66-75 74.20*  
(72.93 – 75.47) 
78.40* 
(74.71 – 82.09) 
74.92*  
(71.31 – 78.54) 
82.94*  
(82.05 – 83.84) 
64.29*  
(61.02 – 67.57) 
79.14*  
(76.55 – 81.73) 
    >=76 78.87*  
(77.57 – 80.16) 
83.30*  
(79.38 – 87.21) 
75.49*  
(71.23 – 79.76) 
72.37*  
(71.32 – 73.43) 
54.86*  
(50.76 – 58.96) 
68.08*  
(64.38 – 71.78) 
Marital status       
    Not married 70.23 ref  
(69.34 –71.11) 
73.30 ref  
(71.24 – 75.35) 
65.51 ref  
(63.48 – 67.54) 
81.48 ref  
(80.91 – 82.05) 
68.65 ref  
(66.93 – 70.36) 
82.34 ref  
(81.06 – 83.63) 
    Married 69.74  
(68.94 – 70.54) 
71.4 0 
(68.15 – 74.64) 
64.18  
(62.08 – 66.28) 
84.87*  
(84.31 – 85.42) 
73.67*  
(71.05 – 76.28) 
85.46*  
(84.07 – 86.86) 
Insurance        
    Uninsured 70.17 ref  
(67.02 –73.32) 
69.26ref 
(62.77 – 75.76) 
67.78 ref  
(63.3 – 72.26) 
77.54 ref 
(74.94 – 80.15) 
70.37 ref  
(64.66 – 76.08) 
80.39 ref  
(77.03 – 83.75) 
    Insured 69.95  
(69.36 – 70.55) 
73.04  
(71.24 – 74.84) 
64.53  
(63.00 – 66.06) 
83.28* 
(82.89 – 83.67) 
70.10  
(68.64 – 71.56) 
84.02*  
(83.06 – 84.98) 
       
       
79 
 
Study Variables Advanced Stage Diagnosis 
% b (95%CI) 
Receipt of Surgery 
% b (95%CI) 
       
       
Stage       
    Non-advanced – – – 93.44 ref  
(92.65 – 94.23) 
88.88 ref  
(86.06 – 91.71) 
96.23 ref  
(94.88 – 97.58)  
    Advanced – – – 80.52  
(80.01 – 81.02)* 
64.78  
(62.93 – 66.63)* 
79.27  
(77.94 – 80.61)* 
Grade        
    Well differentiated 42.45 ref  
(39.31 – 45.59) 
39.32 ref  
(30.31 – 48.33) 
36.80 ref 
(30.39 – 43.21) 
93.52 ref  
(90.88 – 96.15) 
90.74 ref  
(82.19 – 99.29) 
98.23 ref  
(94.96 – 101.49) 
    Moderately    
differentiated 
58.62*  
(56.64 – 60.60) 
61.85*  
(54.97 – 68.74) 
59.70* 
(55.13 – 64.27) 
92.59  
(91.08 – 94.09) 
92.12  
(87.03 – 97.21) 
94.92  
(91.93 – 97.9) 
    Poorly 
differentiated 
73.21*  
(72.13 – 74.30) 
74.58*  
(71.08 – 78.08) 
68.52*  
(65.72 – 71.33) 
92.42  
(91.76 – 93.08) 
86.82  
(84.21 – 89.43) 
92.25*  
(90.65 – 93.85) 
    Undifferentiated 72.69 * 
(71.11 – 74.27) 
79.31*  
(73.64 – 84.98) 
69.85*  
(65.47 – 74.23) 
95.79  
(94.98 – 96.60) 
86.82  
(82.42 – 91.23) 
93.26  
(91.01 – 95.51) 
    Unknown 75.41*  
(74.32 – 76.50) 
77.15* 
(74.48 – 79.82) 
68.01*  
(65.45 – 70.58) 
68.14*  
(67.10 – 69.19) 
52.41*  
(49.58 – 55.24) 
71.39*  
(69.19 – 73.58) 
Histology        
    Serous 82.00 ref  
(81.19 – 82.82) 
82.37 ref  
(79.81 – 84.92) 
79.55 ref  
(77.35 – 81.76) 
88.41 ref  
(87.83 – 89.00) 
78.85 ref  
(76.49 – 81.20) 
89.42 ref  
(88.03 – 90.81) 
    Mucinous 48.46 * 
(44.92 – 51.99) 
56.88*  
(47.7 – 66.06) 
43.12*  
(36.13 – 50.10) 
86.61*  
(84.14 – 89.07) 
68.82*  
(60.47 – 77.17) 
83.13*  
(77.92 – 88.34) 
    Endometrioid 41.87*  
(39.18 – 44.56) 
46.34 * 
(36.54 – 56.14) 
40.68*  
(35.07 – 46.29) 
93.02*  
(90.74 – 95.3) 
83.24  
(72.71 – 93.78) 
94.43*  
(90.13 – 98.72) 
    Clear cell 37.54*  
(34.57 – 40.50) 
58.20*  
(46.07 – 70.32) 
36.09*  
(28.95 – 43.23) 
94.62*  
(92.67 – 96.57) 
83.44  
(71.54 – 95.34) 
90.81  
(85.96 – 95.66) 
    Other or 
unspecified 
68.15*  
(66.89 – 69.41) 
70.21*  
(67.26 – 73.15) 
63.17*  
(60.40 – 65.95) 
75.21*  
(74.38 – 76.05) 
61.98*  
(59.54 – 64.42) 
76.20*  
(74.31 – 78.09) 
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Study Variables Advanced Stage Diagnosis 
% b (95%CI) 
Receipt of Surgery 
% b (95%CI) 
       
       
Contextual-level 
factors: 
      
Metro/nonmetro 
Residence c  
      
    Metro 70.10 ref  
(69.47 – 70.73) 
72.94 ref  
(71.11 – 74.78) 
64.76 ref  
(63.28 – 66.23) 
83.12 ref  
(82.70 – 83.54) 
70.62 ref  
(69.13 – 72.11) 
83.82 ref  
(82.88 – 84.76) 
    Nonmetro 69.03  
(67.28 – 70.78) 
70.6 0 
(63.77 – 77.44) 
67.63  
(59.82 – 75.43) 
83.19  
(82.07 – 84.31) 
64.71  
(58.94 – 70.49) 
80.64  
(75.20 – 86.09) 
County Education d        
    Highest 70.45 ref  
(69.29 – 71.61) 
71.21 ref  
(66.7 – 75.71) 
62.72 ref  
(56.33 – 69.10) 
83.60 ref  
(82.83 – 84.37) 
69.54 ref  
(65.85 – 73.23) 
86.94 ref 
(83.25 – 90.63) 
    Upper-middle 70.21  
(69.03 – 71.40) 
72.17  
(68.69 – 75.65) 
63.26  
(58.68 – 67.84) 
83.11  
(82.33 – 83.88) 
71.13  
(68.37 – 73.90) 
85.01  
(82.24 – 87.79) 
    Lower-middle 69.92  
(68.67 – 71.16) 
73.80  
(70.23 – 77.37) 
63.82  
(60.51 – 67.13) 
82.74  
(81.91 – 83.57) 
71.70  
(68.69 – 74.71) 
83.37  
(81.16 – 85.59) 
    Lowest 68.91  
(67.35 – 70.46) 
73.75  
(69.18 – 78.31) 
66.12  
(63.55 – 68.68) 
82.90  
(81.89 – 83.92) 
67.10  
(63.28 – 70.91) 
83.11  
(81.44 – 84.77) 
County Employment e        
Highest 69.32 ref  
(68.14 – 70.49) 
78.36 ref  
(74.1 – 82.61) 
64.56 ref  
(59.74 – 69.38) 
83.34 ref  
(82.56 – 84.12) 
72.28 ref  
(68.47 – 76.10) 
84.85 ref  
(81.75 – 87.95) 
    Upper-middle 70.68  
(69.50 – 71.87) 
71.05*  
(66.22 – 75.88) 
66.78  
(63.17 – 70.40) 
83.38  
(82.58 – 84.17) 
72.06  
(68.25 – 75.88) 
86.43  
(84.10 – 88.76) 
    Lower-middle 70.16  
(68.82 – 71.50) 
71.34*  
(67.28 – 75.4) 
62.33  
(59.47 – 65.19) 
83.40  
(82.51 – 84.30) 
71.62  
(68.51 – 74.73) 
83.72  
(81.92 – 85.52) 
    Lowest 69.73  
(68.35 – 71.12) 
72.22*  
(68.82 – 75.62) 
66.91  
(63.64 – 70.18) 
82.39  
(81.49 – 83.30) 
67.41  
(64.51 – 70.30) 
81.12  
(78.91 – 83.33) 
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Study Variables Advanced Stage Diagnosis 
% b (95%CI) 
Receipt of Surgery 
% b (95%CI) 
       
County Poverty f       
    Highest 69.04 ref  
(67.75 – 70.33) 
71.58 ref  
(66.13 – 77.04) 
64.37 ref 
(59.65 – 69.09) 
83.41 ref  
(82.55 – 84.26) 
67.83 ref  
(63.25 – 72.41) 
82.06 ref  
(78.63 – 85.48) 
    Upper-middle 69.69  
(68.51 – 70.87) 
70.92  
(66.02 – 75.82) 
62.15  
(57.88 – 66.41) 
82.75  
(81.96 – 83.55) 
67.84  
(63.83 – 71.85) 
82.01  
(78.91 – 85.12) 
    Lower-middle 70.41  
(69.07 – 71.74) 
73.26  
(69.53 – 77.00) 
66.14  
(63.54 – 68.73) 
83.67  
(82.80 – 84.54) 
71.55  
(68.6 – 74.50) 
84.1  
(82.52 – 85.67) 
    Lowest 71.03  
(69.51 – 72.54) 
73.42  
(70.06 – 76.79) 
65.20  
(60.75 – 69.65) 
82.67  
(81.67 – 83.67) 
70.60  
(67.77 – 73.43) 
85.22  
(82.70 – 87.73) 
Notes: a Adjusted for all the variables listed and year of diagnosis. b Average adjusted predicted probabilities. c Metro vs. nonmetro categories are based on the Rural-
Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S. Department of Agriculture. d Sorted by percentage of a county 
population with less than 9th grade education in ascending order, and categorized into quartiles.  e Sorted by percentage of persons aged 16 and over who are 
unemployed in a county in ascending order, and categorized into quartiles. f Sorted by percentage of persons in a county whose incomes are below the 100% federal 
poverty level threshold in ascending order, and categorized into quartiles.  
CI, confidence interval. ref reference group. * p<0.05 
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Appendix C: Table 4.1 
 
Model with Insurance Status: Adjusted Hazard Ratios for Ovarian Cancer-Cause Specific 
Mortality a 
 
Study Variables Ovarian Cancer-Cause 
Specific Mortality 
(N=27,539) 
HR (95%CI) 
Race/ethnicity   
    Non-Hispanic White Ref. 
    Non-Hispanic Black 0.79 (0.56 – 1.10) 
    Hispanic 0.80 (0.60 – 1.07) 
    Other 0.93 (0.61 – 1.40) 
Age at diagnosis  
    18-45 Ref. 
    46-55 1.29 (1.17 – 1.43)* 
    56-65 1.46 (1.33 – 1.61)* 
    66-75 1.78 (1.62 – 1.96)* 
    >=76 2.56 (2.32 – 2.82)* 
Marital status  
    Not married Ref. 
    Married 0.86 (0.82 – 0.90)* 
Insurance   
    Uninsured Ref. 
    Insured 0.80 (0.69 – 0.94)* 
Stage  
    Non-advanced Ref. 
    Advanced 3.93 (3.63 – 4.26)* 
Surgery  
    No Ref. 
    Yes 0.29 (0.27 – 0.31)* 
Grade   
    Well differentiated Ref. 
    Moderately differentiated 2.11 (1.73 – 2.56)* 
    Poorly differentiated 2.75 (2.28 – 3.31)* 
    Undifferentiated 2.60 (2.14 – 3.15)* 
    Unknown 2.51 (2.08 – 3.03)* 
Histology   
    Serous Ref. 
    Mucinous 1.77 (1.56 – 2.00)* 
    Endometrioid 0.75 (0.66 – 0.86)* 
    Clear cell 1.42 (1.26 – 1.59)* 
    Other or unspecified 1.35 (1.28 – 1.42)* 
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Study Variables Ovarian Cancer-Cause 
Specific Mortality 
(N=27,539) 
HR (95%CI) 
Interaction: 
Race/ethnicity * insurance  
    NHW * uninsured Ref. 
    NHB * insured 1.56 (1.11 – 2.20)* 
    Hispanic * insured 1.29 (0.96 – 1.73) 
    Other * insured 1.08 (0.71 – 1.65) 
  
Contextual-level factors:  
Metro/nonmetro residence b  
    Metro Ref. 
    Nonmetro 1.13 (1.05 – 1.21)* 
County education c  
    Highest Ref. 
    Upper-middle 0.96 (0.90 – 1.03) 
    Lower-middle 0.98 (0.91 – 1.05) 
    Lowest 1.00 (0.92 – 1.08) 
County employment  d  
    Highest Ref. 
    Upper-middle 0.93 (0.87 – 0.99)* 
    Lower-middle 0.96 (0.89 – 1.03) 
    Lowest 1.01 (0.94 – 1.09) 
County poverty e  
    Highest Ref. 
    Upper-middle 1.05 (0.98 – 1.13) 
    Lower-middle 1.02 (0.94 – 1.10) 
    Lowest 1.05 (0.96 – 1.14) 
  
Random effect  
County variance 0.0015 
 
Notes: a Adjusted for all the variables listed in the table, year of diagnosis, interaction between race/ethnicity and 
insurance status, and county random effect. b Metro vs. nonmetro categories are based on the Rural-Urban 
Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S. Department of 
Agriculture. c Sorted by percentage of a county population with less than 9th grade education in ascending order, and 
categorized into quartiles.  d Sorted by percentage of persons aged 16 and over who are unemployed in a county in 
ascending order, and categorized into quartiles. e Sorted by percentage of persons in a county whose incomes are 
below the 100% federal poverty level threshold in ascending order, and categorized into quartiles.  
HR, hazard ratio. CI, confidence interval. Ref., reference group. * p<0.05 
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Appendix D: Table 5.1 
  
Models with Insurance Status: Factors Contributing to Disparities in Ovarian Cancer-Cause 
Specific Mortality, by Race/Ethnicity a 
 
Study Variables Ovarian Cancer-Cause Specific Mortality 
HR (95%CI) 
 Non–Hispanic 
White 
(n=19.328) 
Non–Hispanic 
Black 
(n=2,278) 
Hispanic 
(n=3,460) 
Age at diagnosis    
    18-45 Ref. Ref. Ref. 
    46-55 1.34 (1.17 – 1.53)* 1.18 (0.90 – 1.55) 1.30 (1.03 – 1.64)* 
    56-65 1.53 (1.35 – 1.74)* 1.24 (0.96 – 1.62) 1.49 (1.19 – 1.87)* 
    66-75 1.88 (1.66 – 2.14)* 1.31 (1.01 – 1.71)* 1.88 (1.48 – 2.39)* 
    >=76 2.75 (2.42 – 3.13)* 1.86 (1.42 – 2.45)* 2.55 (1.97 – 3.29) 
Marital status    
    Not married Ref. Ref. Ref. 
    Married 0.84 (0.80 – 0.89)* 0.88 (0.75 – 1.02) 0.93 (0.81 – 1.07) 
Insurance     
    Uninsured Ref. Ref. Ref. 
    Insured 0.79 (0.68 – 0.93)* 1.36 (0.99 – 1.86) 1.03 (0.8 – 1.34) 
Stage    
    Non-advanced Ref. Ref. Ref. 
    Advanced 3.93 (3.57 – 4.33)* 2.94 (2.32 – 3.74)* 4.95 (3.88 – 6.33)* 
Surgery    
    No Ref. Ref. Ref. 
    Yes 0.30 (0.28 – 0.33)* 0.29 (0.24 – 0.35)* 0.26 (0.21 – 0.31)* 
Grade     
    Well differentiated Ref. Ref. Ref. 
    Moderately     
differentiated 
2.05 (1.62 – 2.59)* 2.15 (1.17 – 3.95)* 2.04 (1.19 – 3.49)* 
    Poorly 
differentiated 
2.67 (2.14 – 3.34)* 3.11 (1.79 – 5.41)* 2.82 (1.69 – 4.68)* 
    Undifferentiated 2.48 (1.97 – 3.12)* 3.26 (1.81 – 5.86)* 2.82 (1.66 – 4.78)* 
    Unknown 2.57 (2.05 – 3.22)* 2.43 (1.39 – 4.23)* 2.09 (1.25 – 3.50)* 
Histology     
    Serous Ref. Ref. Ref. 
    Mucinous 1.69 (1.45 – 1.97)* 2.12 (1.53 – 2.95)* 2.31 (1.66 – 3.20)* 
    Endometrioid 0.75 (0.64 – 0.88)* 0.57 (0.34 – 0.96)* 1.08 (0.77 – 1.50) 
    Clear cell 1.31 (1.13 – 1.51)* 1.73 (1.09 – 2.75)* 2.43 (1.72 – 3.43)* 
    Other or 
unspecified 
1.30 (1.22 – 1.38)* 1.43 (1.22 – 1.68 * 1.65 (1.41 – 1.93)* 
    
Contextual-Level 
Factors: 
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Study Variables Ovarian Cancer-Cause Specific Mortality 
HR (95%CI) 
 Non–Hispanic 
White 
(n=19.328) 
Non–Hispanic 
Black 
(n=2,278) 
Hispanic 
(n=3,460) 
Metro/nonmetro 
residence b 
   
    Metro Ref. Ref. Ref. 
    Nonmetro 1.14 (1.05 – 1.23)* 1.07 (0.82 – 1.39) 1.20 (0.87 – 1.66) 
County education c    
    Highest Ref. Ref. Ref. 
    Upper-middle 0.95 (0.88 – 1.02) 1.02 (0.82 – 1.28) 1.10 (0.79 – 1.52) 
    Lower-middle 0.98 (0.91 – 1.06) 0.96 (0.75 – 1.21) 1.12 (0.83 – 1.52) 
    Lowest 0.95 (0.87 – 1.04) 1.18 (0.93 – 1.49) 1.17 (0.84 – 1.62) 
County employment d     
    Highest Ref. Ref. Ref. 
    Upper-middle 0.93 (0.87 – 1.00) 0.85 (0.66 – 1.09) 0.80 (0.62 – 1.03) 
    Lower-middle 0.99 (0.92 – 1.07) 0.92 (0.73 – 1.15) 0.73 (0.56 – 0.96)* 
    Lowest 0.98 (0.91 – 1.07) 1.14 (0.91 – 1.43) 0.84 (0.65 – 1.08) 
County poverty e    
    Highest Ref. Ref. Ref. 
    Upper-middle 1.06 (0.99 – 1.14) 0.97 (0.75 – 1.26) 0.80 (0.62 – 1.03) 
    Lower-middle 1.03 (0.95 – 1.12) 0.89 (0.69 – 1.15) 0.73 (0.56 – 0.96) 
    Lowest 1.12 (1.02 – 1.22)* 0.76 (0.59 – 0.99)* 0.84 (0.65 – 1.08) 
Notes: a Adjusted for all the variables listed in the table and year of diagnosis. b Metro vs. nonmetro categories are 
based on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S. 
Department of Agriculture. c Sorted by percentage of a county population with less than 9th grade education in 
ascending order, and categorized into quartiles.  d Sorted by percentage of persons aged 16 and over who are 
unemployed in a county in ascending order, and categorized into quartiles. e Sorted by percentage of persons in a 
county whose incomes are below the 100% federal poverty level threshold in ascending order, and categorized into 
quartiles.  
HR, hazard ratio. CI, confidence interval. Ref., reference group. * p<0.05 
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Appendix E: Table 6  
 
Racial/ethnic Disparities in Advanced Stage Diagnosis, Receipt of Surgery and Survival: Trend over time, 2001-2012 
 
Year Late Stage Diagnosis (OR) Receipt of Surgery (OR) Ovarian Cancer Mortality (HR) 
  
NHW vs. 
NHB 
NHW vs. 
Hispanic 
NHB vs. 
Hispanic 
NHW vs. 
NHB 
NHW vs. 
Hispanic 
NHB vs. 
Hispanic 
NHW vs. 
NHB 
NHW vs. 
Hispanic 
NHB vs. 
Hispanic 
    2001 1.06 0.89 0.75 0.39 1.23 3.91 1.52 1.02 0.72 
    2002 1.24 1.17 0.79 0.46 0.75 1.47 1.03 0.84 0.73 
    2003 1.02 1.15 1.17 0.44 0.61 1.40 1.47 0.98 0.68 
    2004 0.99 1.07 1.14 0.50 0.83 1.86 1.24 0.94 0.72 
    2005 0.96 1.06 1.03 0.61 0.93 1.73 1.28 0.98 0.66 
    2006 1.05 0.68 0.60 0.33 1.14 3.63 1.17 1.14 0.95 
    2007 0.98 1.19 0.98 0.33 0.77 2.24 1.21 1.00 0.72 
    2008 1.27 1.02 0.73 0.53 0.62 1.36 1.17 0.94 0.76 
    2009 1.10 1.17 0.89 0.56 0.67 1.19 1.22 1.22 1.01 
    2010 1.02 1.08 1.07 0.53 0.82 1.52 1.21 1.16 0.94 
    2011 1.01 0.76 0.78 0.64 0.82 1.54 1.18 0.82 0.6 
    2012 1.52 1.22 0.71 0.56 0.84 1.56 1.02 0.99 0.73 
AAPC*(%) 1.24 0.00 -1.28 2.95 -1.09 -3.86 -1.48 1.12 1.57 
P value 0.30 1.00 0.50 0.10 0.55 0.20 0.17 0.32 0.29 
OR, odds, ratio. *Average Annual Percent Change
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Appendix F: Table 2.2 
Adjusted Odds Ratio of Advanced Stage Diagnosis and Receipt of Surgery a 
Study Variables Advanced Stage Diagnosis Receipt of Surgery 
 (N=54,580) (N=54,580) 
 OR (95%CI) OR (95%CI) 
Race/ethnicity   
    Non-Hispanic White Ref. Ref. 
    Non-Hispanic Black 1.47 (1.18 – 1.84)* 0.48 (0.43 – 0.54)* 
    Hispanic 0.90 (0.75 – 1.09) 0.82 (0.74 – 0.92)* 
    Other 1.12 (0.95 – 1.31) 0.82 (0.71 – 0.94)* 
Age at diagnosis   
    18-45 Ref. Ref. 
    46-55 1.68 (1.57 – 1.80)* 0.41 (0.35 – 0.48)* 
    56-65 2.38 (2.23 – 2.55)* 0.25 (0.21 – 0.29)* 
    66-75 3.04 (2.83 – 3.27)* 0.16 (0.14 – 0.18)* 
    >=76 3.93 (3.63 – 4.25)* 0.06 (0.05 – 0.07)* 
Marital status   
    Not married Ref. Ref. 
    Married 0.95 (0.90 – 0.99)* 1.53 (1.43 – 1.64)* 
Stage   
    Non-advanced Ref. Ref. 
    Advanced – 0.10 (0.09 – 0.11) 
Grade    
    Well differentiated Ref. Ref. 
    Moderately 
differentiated 
2.28 (2.07 – 2.51)* 1.13 (0.84 – 1.51) 
    Poorly differentiated 4.95 (4.52 – 5.42)* 1.00 (0.77 – 1.32) 
    Undifferentiated 4.67 (4.20 – 5.19)* 1.56 (1.16 – 2.09)* 
    Unknown 4.66 (4.25 – 5.11)* 0.10 (0.07 – 0.12)* 
Histology    
    Serous Ref. Ref. 
    Mucinous 0.19 (0.17 – 0.21)* 0.49 (0.42 – 0.58)* 
    Endometrioid 0.15 (0.14 – 0.16)* 1.54 (1.21 – 1.96)* 
    Clear cell 0.11 (0.10 – 0.12)* 1.81 (1.42 – 2.30)* 
    Other or unspecified 0.45 (0.42 – 0.47)* 0.18 (0.16 – 0.19)* 
   
Interaction: 
race/ethnicity*county 
employment 
  
NHW * highest Ref.  
NHB * upper middle 0.76 (0.56 – 1.01) – 
NHB * lower middle 0.71 (0.54 – 0.93)* – 
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NHB * lowest 0.71 (0.54 – 0.92)* – 
Hispanic * upper middle 1.12 (0.88 – 1.42) – 
Hispanic * lower middle 1.14 (0.92 – 1.42) – 
Hispanic * lowest 1.17 (0.93 – 1.49) – 
Other * upper middle 0.83 (0.66 – 1.04) – 
Other * lower middle 0.71 (0.58 – 0.87)* – 
Other * lowest 0.88 (0.67 – 1.17) – 
   
Contextual-level 
factors: 
  
Metro/nonmetro residence b  
    Metro Ref. Ref. 
    Nonmetro 0.98 (0.90 – 1.05) 0.94 (0.83 – 1.05) 
County education c   
    Highest Ref. Ref. 
    Upper-middle 0.94 (0.87 – 1.01) 1.04 (0.91 – 1.18) 
    Lower-middle 0.97 (0.89 – 1.05) 0.99 (0.86 – 1.14) 
    Lowest 0.93 (0.84 – 1.01) 1.03 (0.89 – 1.19) 
County employment d   
    Highest Ref. Ref. 
    Upper-middle 1.06 (0.98 – 1.15) 0.99 (0.88 – 1.11) 
    Lower-middle 1.07 (0.99 – 1.17) 1.00 (0.88 – 1.13) 
    Lowest 1.02 (0.93 – 1.13) 0.89 (0.78 – 1.03) 
County poverty e   
    Highest Ref. Ref. 
    Upper-middle 1.04 (0.97 – 1.13) 0.90 (0.79 – 1.03) 
    Lower-middle 1.13 (1.03 – 1.24)* 0.91 (0.78 – 1.06) 
    Lowest 1.16 (1.05 – 1.28)* 0.89 (0.76 – 1.05) 
   
Random effect   
County variance 0.007 0.0451* 
Notes: a Adjusted for all the variables listed in the table, year of diagnosis, interaction between race/ethnicity and 
county employment, and county random effects. b Metro vs. nonmetro categories are based on the Rural-Urban 
Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S. Department of 
Agriculture. c Sorted by percentage of a county population with less than 9th grade education in ascending order, and 
categorized into quartiles.  d Sorted by percentage of persons aged 16 and over who are unemployed in a county in 
ascending order, and categorized into quartiles. e Sorted by percentage of persons in a county whose incomes are 
below the 100% federal poverty level threshold in ascending order, and categorized into quartiles.   
OR, odds ratio. CI, confidence interval. Ref. reference group. 
*
 p<0.05 
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Appendix G: Table 3.2  
Factors Contributing to Disparities in Advanced Stage Diagnosis and Receipt of Surgery, by Race/Ethnicity (Odds Ratio) a 
Study Variables Advanced Stage Diagnosis 
OR(95%CI) 
Receipt of Surgery 
OR (95%CI) 
 Non–Hispanic 
White 
(n=39,726) 
Non–Hispanic 
Black 
(n=4,295) 
Hispanic 
(n=6,256) 
Non–Hispanic 
White 
(n=39,726) 
Non–Hispanic 
Black 
(n=4,295) 
Hispanic 
(n=6,256) 
Age at diagnosis       
    18-45 Ref. Ref. Ref. Ref. Ref. Ref 
    46-55 1.71 (1.56 – 1.86)* 1.67 (1.33 – 2.10)* 1.74 (1.48 – 2.06)* 0.45 (0.36 – 0.57)* 0.48 (0.33 – 0.68)* 0.27 (0.19 – 0.38)* 
    56-65 2.38 (2.18 – 2.59)* 2.43 (1.93 – 3.05)* 2.63 (2.19 – 3.15)* 0.25 (0.21 – 0.31)* 0.28 (0.20 – 0.39)* 0.24 (0.17 – 0.33)* 
    66-75 3.03 (2.77 – 3.32)* 2.88 (2.25 – 3.68)* 3.28 (2.68 – 4.02)* 0.16 (0.13 – 0.20)* 0.18 (0.13 – 0.25)* 0.14 (0.10 – 0.19)* 
    >=76 3.95 (3.60 – 4.34)* 4.03 (3.05 – 5.31)* 3.70 (2.92 – 4.68)* 0.06 (0.05 – 0.07)* 0.09 (0.06 – 0.13)* 0.05 (0.03 – 0.07)* 
Marital status       
    Not married Ref. Ref. Ref. Ref. Ref. Ref 
    Married 0.94 (0.89 – 0.99)* 0.88 (0.74 – 1.04) 0.93 (0.82 – 1.06) 1.59 (1.47 – 1.72)* 1.51 (1.22 – 1.86)* 1.31 (1.08 – 1.60)* 
Stage       
    Non-advanced Ref. Ref. Ref. Ref. Ref. Ref 
    Advanced – – – 0.11 (0.09 – 0.12)* 0.11 (0.08 – 0.14)* 0.06 (0.04 – 0.08)* 
Grade        
    Well 
differentiated 
Ref. Ref. Ref. Ref. Ref.  Ref 
    Moderately 
differentiated 2.18 (1.95 – 2.45)* 2.80 (1.95 – 4.02)* 2.74 (2.09 – 3.60)* 1.30 (0.93 – 1.81) 0.51 (0.17 – 1.53) 0.75 (0.27 – 2.10) 
    Poorly 
differentiated 4.78 (4.29 – 5.33)* 5.38 (3.83 – 7.55)* 5.06 (3.91 – 6.53)* 1.25 (0.92 – 1.69) 0.35 (0.12 – 0.99)* 0.63 (0.24 – 1.64) 
    
Undifferentiated 4.48 (3.96 – 5.07)* 5.64 (3.72 – 8.53)* 5.17 (3.79 – 7.03)* 2.14 (1.53 – 2.99)* 0.40 (0.13 – 1.20) 0.67 (0.24 – 1.83) 
    Unknown 4.66 (4.17 – 5.20)* 5.42 (3.89 – 7.55)* 4.38 (3.40 – 5.64)* 0.11 (0.08 – 0.15)* 0.04 (0.01 – 0.11)* 0.06 (0.02 – 0.16)* 
Histology        
    Serous Ref. Ref. Ref. Ref. Ref. Ref 
    Mucinous 0.18 (0.16 – 0.20)* 0.26 (0.19 – 0.36)* 0.21 (0.17 – 0.27)* 0.49 (0.40 – 0.60)* 0.47 (0.30 – 0.75)* 0.55 (0.35 – 0.88)* 
    Endometrioid 0.14 (0.13 – 0.15)* 0.16 (0.12 – 0.22)* 0.17 (0.14 – 0.21)* 1.45 (1.09 – 1.92)* 1.26 (0.65 – 2.44) 2.32 (1.03 – 5.25)* 
    Clear cell 0.11 (0.10 – 0.12)* 0.17 (0.11 – 0.26)* 0.13 (0.10 – 0.17)* 2.05 (1.51 – 2.78)* 0.90 (0.42 – 1.95) 1.19 (0.64 – 2.21) 
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Study Variables Advanced Stage Diagnosis 
OR(95%CI) 
Receipt of Surgery 
OR (95%CI) 
 Non–Hispanic 
White 
(n=39,726) 
Non–Hispanic 
Black 
(n=4,295) 
Hispanic 
(n=6,256) 
Non–Hispanic 
White 
(n=39,726) 
Non–Hispanic 
Black 
(n=4,295) 
Hispanic 
(n=6,256) 
    Other or 
unspecified 
0.47 (0.44 – 0.50)* 
0.42 (0.34 – 0.51)* 0.39 (0.34 – 0.46)* 0.17 (0.16 – 0.19)* 0.22 (0.18 – 0.27)* 0.17 (0.14 – 0.22)* 
       
Contextual-Level 
Factors: 
      
Metro/nonmetro 
Residence b 
      
    Metro Ref. Ref. Ref. Ref. Ref. Ref 
    Nonmetro 0.98 (0.91 – 1.07) 0.78 (0.58 – 1.06) 0.95 (0.67 – 1.35) 1.01 (0.89 – 1.16) 0.86 (0.60 – 1.23) 0.79 (0.47 – 1.34) 
County  
Education c 
      
    Highest Ref. Ref. Ref. Ref. Ref. Ref 
    Upper-middle 0.94 (0.87 – 1.01) 1.02 (0.78 – 1.33) 0.88 (0.65 – 1.21) 1.03 (0.90 – 1.19) 1.27 (0.92 – 1.76) 0.85 (0.51 – 1.41) 
    Lower-middle 0.95 (0.86 – 1.04) 1.23 (0.92 – 1.64) 1.02 (0.74 – 1.39) 0.98 (0.84 – 1.15) 1.15 (0.82 – 1.63) 0.84 (0.52 – 1.36) 
    Lowest 0.92 (0.83 – 1.02) 1.10 (0.81 – 1.48) 0.97 (0.70 – 1.35) 0.97 (0.81 – 1.16) 0.95 (0.66 – 1.37) 0.97 (0.58 – 1.62) 
County 
Employment d 
      
    Highest Ref. Ref. Ref. Ref. Ref. Ref 
    Upper-middle 1.06 (0.98 – 1.15) 0.77 (0.57 – 1.05) 1.19 (0.92 – 1.54) 1.01 (0.89 – 1.15) 0.94 (0.66 – 1.35) 0.84 (0.56 – 1.26) 
    Lower-middle 1.07 (0.99 – 1.17) 0.71 (0.54 – 0.95)* 1.09 (0.82 – 1.45) 0.95 (0.83 – 1.10) 1.20 (0.86 – 1.68) 0.74 (0.48 – 1.15) 
    Lowest 1.04 (0.95 – 1.15) 0.66 (0.49 – 0.90)* 1.06 (0.78 – 1.42) 0.98 (0.83 – 1.15) 0.76 (0.53 – 1.09) 0.62 (0.39 – 0.97)* 
County Poverty e       
    Highest Ref. Ref. Ref. Ref. Ref. Ref 
    Upper-middle 1.05 (0.97 – 1.14) 1.04 (0.76 – 1.41) 1.01 (0.77 – 1.32) 0.90 (0.77 – 1.04) 0.86 (0.59 – 1.25) 1.03 (0.69 – 1.55) 
    Lower-middle 1.11 (1.01 – 1.22)* 1.09 (0.80 – 1.48) 1.22 (0.90 – 1.63) 0.91 (0.77 – 1.08) 1.04 (0.72 – 1.51) 0.88 (0.57 – 1.37) 
    Lowest 1.14 (1.02 – 1.28)* 1.25 (0.91 – 1.72) 1.37 (0.99 – 1.91) 0.80 (0.66 – 0.97)* 1.14 (0.78 – 1.68) 1.00 (0.61 – 1.62) 
       
Random Effect       
County Variance 0.0031 <0.0001 0.0248 0.0527* <0.0001 <0.0001 
Notes: a Adjusted for all the variables listed in the table, year of diagnosis and county random effects. b Metro vs. nonmetro categories are based on the Rural-
Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S. Department of Agriculture. c Sorted by percentage of a county 
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population with less than 9th grade education in ascending order, and categorized into quartiles.  d Sorted by percentage of persons aged 16 and over who are 
unemployed in a county in ascending order, and categorized into quartiles. e Sorted by percentage of persons in a county whose incomes are below the 100% 
federal poverty level threshold in ascending order, and categorized into quartiles.  
OR, odds ratio. CI, confidence interval. Ref. reference group. 
*
 p<0.05 
 
